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Castleman disease (CD) is a lymphoproliferative disorder with four subtypes, some of 
which are aetiologically linked to Human Herpes virus 8 (HHV-8) which is known to 
cause diseases preferentially occurring in HIV-infected individuals.  There has been a 
notable increase in the number of patients with HIV/HHV-8 associated CD diagnosed in 
the Groote Schuur hospital complex.  
Aims 
The aim of the study was to determine the role of DC-SIGN, DC-SIGNR, p24 and HHV-8 
(LANA-1) in Castleman disease. Our objectives were to identify the presence of DC-
SIGN and DC-SIGNR in HHV-8 infected cells, determine whether HHV-8 and p24 (HIV) 
co-infection occurs in the same cells and to determine whether HHV-8 infects B and/or T 
cells.  This study not only represents the largest and first immunophenotypic investigative 
evaluation of CD but also signifies the first double staining immunohistochemical analysis 
of CD diagnosed at Groote Schuur hospital. 
Methods 
This was both a retrospective descriptive as well as an analytic cross-sectional 
immunohistochemistry study. Fifty cases of CD diagnosed at the Division of Anatomical 
Pathology, National Health Laboratory Service, Groote Schuur hospital over a ten and half 
year period were included in the study. Double immunohistochemistry was used to 
characterise HHV-8 infected cells using LANA-1 antibody, in conjunction with DC-
SIGN, DC-SIGNR, p24, CD20 and CD3. Immunophenotypic analysis was then performed 
to assess 1) the number of infected HHV-8 cells and 2) number and distribution of cells 
co-expressing HHV-8 and DC-SIGN, DC-SIGNR, p24, CD20 and CD3. The 
immunophenotypic profiles were then compared to the CD morphologic subtypes.  
Results 
The study cohort included 26 male and 24 female patients (M: F = 1.08:1), mean age 37.7 
years.  There were 16 hyaline vascular CD (HV-CD), 16 plasmablastic CD (Pb-CD).  Nine 
plasma cell CD and 9 mixed-CD subtypes. There was a statistically significant association 
between HIV (n=45) and HHV-8 (n=40) positivity (p < 0.0002).  CD4 counts and 
HAART enrolment were not predictive of CD development (p = 0.6120). Concurrent 
Kaposi sarcoma was seen in 16% (n=8) of the cohort.  
 vi 
When comparing Pb-CD and HV-CD, there were statistically significant differences in 
density of LANA-1 infected cells (p<0.0002), LANA-1/DC-SIGN co-expressing cells (p 
<0.0072) and LANA-1/p24 co-expressing cells (p<0.0001).  
Conclusions 
The findings of this study suggest that DC-SIGN may have a role in HHV-8 entry into 
cells. Furthermore, there is evidence that HIV and HHV-8 co-infection may function 
synergistically in CD. It is possible that DC-SIGN and DC-SIGNR facilitate dual viral 
entry into cells and influence viral replication and persistent infection. 
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Castleman disease (CD), previously known as giant lymph node hyperplasia, lymphoid 
hamartoma and angiofollicular hyperplasia; is a heterogenous, non-clonal 
lymphoproliferative disorder often accompanied by a constellation of clinical features and 
a variety of constitutional symptoms.   
 
The observation that Castleman disease could arise in more than one region, led to the first 
clinical classification system for the disease. Clinically it can manifest in a localised form 
referred to as unicentric Castleman Disease (UCD) with mild symptoms; or in a 
multicentric form referred to as multicentric Castleman disease (MCD) characterised by a 
myriad of systemic symptoms and abnormal laboratory investigations.   
 
The main driver for the dysregulation of the immune system in either form is viral 
interleukin-6 (vIL-6), aetiologically linked to Herpes Human virus 8 (HHV-8)/Kaposi 
Sarcoma Herpes Virus (KSHV) (El-Osta & Kurzrock, 2011).  Cases of CD not showing 
any demonstrable infection with HHV-8 (serologically or immunohistochemically) are 
currently referred to as idiopathic MCD (iMCD) (Fajgenbaum et al., 2016). Although 
these cases frequently display similar immunological dysfunction observed in viral related 
cases, the associated hyperactivation of the immune system is mainly due to human 
interleukin-6 (hIL-6) elaboration (Fajgenbaum et al., 2014; Liu et al., 2016). 
 
Since its initial description, the histopathological classification has also expanded, with the 
four commonly recognised histopathological subtypes of CD: hyaline vascular (HV-CD), 
plasma cell (PC-CD), mixed, and more recently the plasmablastic (Pb-CD) subtype.  
 
Pb-CD lymph node changes are only seen in cases of HHV-8-associated MCD. Previously 
associated with severe immunosuppression, it is now being encountered with increasing 
frequency in HIV infected patients, regardless of HAART or CD4 counts (Mylona et al., 
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The 2016 South African HIV adult prevalence (15–49 years) in South Africa is 18.9 %, 
which translates into an estimated 7.1 million individuals infected with HIV.  South Africa 
also has the largest ART programme worldwide with more than 3.6million people on 
HAART.  The life expectancy of people living with HIV has significantly increased from 
53.4 years in 2004 to 62.5 years in 2015, which is accompanied by increasing incidences 
of co-morbidity, specifically lymphoproliferative disorders (Statistics South Africa, 2016). 
The reported seroprevalence of HHV-8 in South Africa is 44%-48% (Malope et al., 2008; 
Maskew et al., 2011). These statistics are noteworthy as the oncogenic potential of HHV-8 
is known to dramatically elevate the risk for lymphoid malignancies occurring within 
immunodeficient populations. Furthermore, HIV has recently been shown to also have 
oncogenic potential.  
 
Our hospital complex (GSH) provides health care services to a large population of patients 
in Cape Town metropole and surrounds. Although the province has South Africa’s lowest 
HIV prevalence rates, it has one of the highest HHV-8 seroprevalence rates. This, in 
combination with migratory factors most likely play important roles in the increased 
incidence of HIV/HHV-8 associated CD diagnosed in GSH.  Migratory factors may 
indeed contribute to shaping the demographic of the disease in our hospital setting as the 
Western Cape is also known to have one of the highest migration streams in South Africa 
(Statistics South Africa, 2016).   
 
This is pertinent as sub-Saharan Africa has a disproportionately high HHV-8 
seroprevalence rate. The reason for the increased risk of the disease while on HAART has 
not been clearly defined and current knowledge of the pathophysiology of HIV related 
disease is still limited.  The study objectives were primarily to determine the presence and 
role of DC-SIGN presence in HHV-8 infected cells, determine whether HHV-8 and p24 
(HIV) co-infection occurs in the same cells and to determine whether HHV-8 infects B 
and/or T cells so as to gain further insight into the pathogenesis of Castleman disease. The 
rarity of the disease underlies the paucity of studies emerging from the South African 
context however it is becoming increasingly apparent that we need to improve our current 
knowledge of CD, especially HIV-associated CD. Documentation of the various 
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demographic aspects of the disease will be of historical, clinical and pathological interest 
as the long term effects of highly active antiretroviral therapy (HAART) begin to emerge.   
 
It is our hope that our findings contribute to the expanding body of work generated by this 
intriguing disease, improve understanding of the biochemical intricacies of the co-infected 
HIV-HHV-8 microenviroment and ultimately generate new information leading to 
additional advances in early therapeutic and preventative strategies for HIV positive 
patients at risk for HHV-8 related disease.  
 
1.2 Historical perspective 
Castleman disease was first described by Dr Benjamin Castleman, a pathologist at 
Massachusetts General Hospital, in a 1954 case report of two patients and again in 1956 in 
a case series of 13 patients (Castleman & Towne, 1954; Castleman et al., 1956).  The 
histological descriptors currently in use were first described in the late 1960s and early 
1970s.  It was around this time that Flendrig and Schillings (1969) observed that some 
lymph nodes of patients with the disease were enriched with plasma cell infiltrates rather 
than the prominent vascular hyalinisation previously described.  Keller et al. (1972) were 
amongst the first researchers who used the terms hyaline-vascular (HV) and plasma-cell 
(PC) to describe the two main recognised subtypes of CD.  They also further refined the 
characterisation of the plasma-cell subtype, which although less common, was more 
frequently associated with systemic signs and symptoms.  They observed that the involved 
lymph nodes in this subtype differed little from normal lymph node histology and did not 
show evidence of prominent vascular hyalinization. The patients with this subtype often 
presented with generalised lymphadenopathy and were more likely to have a protracted 
clinical course and systemic B-symptoms, which included anaemia, pancytopaenia and 
hypergammaglobulinaemia.  As a result of these very specific findings, the first case of 
MCD was reported in 1978 while the salient differences between hyaline-vascular and 
plasma-cell subtypes were further refined (Gaba et al., 1978).    
 
The observation of synchronous Kaposi sarcoma (KS) and MCD was first described in 
1985 (Lachant et al., 1985).  It was only when Chang and associates discovered a novel 
Gamma-Herpes virus in 1994, which was subsequently named Human Herpesvirus 8 
(HHV-8)/Kaposi sarcoma Herpes virus (KSHV), that the first cases of HHV-8 associated 
MCD were described (Chang et al., 1994; Cesarman et al., 1995).  Following this, a causal 
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link between HHV-8 and KS was then identified in both HIV-positive and HIV-negative 
patients in the mid 1990s (Moore and Chang, 1998).  Soulier et al. (1995a) then reported 
on the presence HHV-8 sequences in the lymph nodes of both HIV-positive and HIV-
negative patients with MCD.  Other investigators later confirmed that virtually all HIV-
positive CD cases contained HHV-8 in their affected lymph nodes and that only half of 
HIV-negative MCD were HHV-8 positive (Dispenzieri et al., 2012).  Detection of HHV-8 
LANA-1 has therefore been crucial in the diagnosis of HHV-8 associated cases.  
Consequently, the absence of HHV-8 almost always excludes HIV related disease 
(Marcelin et al., 2003).  Yoshizaki et al. (1989) were the first researchers to report the 
elevated levels of interleukin 6 (IL-6) by B-lymphocytes in the germinal centres in CD 
lymph nodes.  This novel discovery eventually led to the development of anti-IL6 and 
anti-IL6R monoclonal antibodies as treatment options for CD (Beck et al., 1994; 
Nishimoto et al., 2000; van Rhee  et al., 2015).  The identification of the additional 
elaboration of the vIL-6, which is primarily encoded by HHV-8 in both MCD and KS, 
further cemented the relationship between these two diseases (Aoki et al., 1999).  
  
1.3 Classification 
 Current classification 
Historically, the classification of CD has been based on both clinical and radiological 
parameters at the time of diagnosis.  These findings usually distinguish two distinct 
entities that usually correspond with relevant symptomatology: being either UCD or MCD 
at presentation.  Histologically, the disease is further subdivided into four subtypes: 
hyaline-vascular (HV), plasma-cell (PC), mixed and the more recently described 
plasmablastic subtype, which is associated with more aggressive disease and seen only in 
HIV/HHV-8-associated cases (Cronin & Warnke, 2009).  It remains controversial as to 
whether CD subtypes represent different stages of the same disease or whether they are 
entirely separate disease entities. Even as early as the 1970s, when the disease was first 
being described, there was recognition that both UCD and MCD were often part of a 
continuous spectrum that ranged from unifocal, unicentric disease to multicentric disease 
which Keller et al (1972) claimed reflected the evolution of CD with time.  This view was 
validated by reports of transitions between HV and PC subtypes on follow-up biopsies of 
affected patients as well as by the simultaneous presence of both subtypes at separate sites 
within the same patient (Keller et al., 1972). 
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The frequent finding of co-existent HV- and PC-CD (mixed subtype) in the same lymph 
node, especially in the setting of HHV-8 infection, strongly favours the argument of a 
single disease with variable histopathology during the evolution of the disease.  As there 
are no official diagnostic criteria for HIV/HHV-8 associated CD or specific laboratory 
tests to confirm its presence, it is important that a surgically excised lymph node be 
histologically and immunohistochemically evaluated once the diagnosis is suspected.  This 
not only helps to render the correct diagnosis but also helps to exclude reactive states, 
autoimmune diseases and malignancies that can cause atypical lymph node hyperplasia 
with overlapping histopathological features (Soma & Kara, 2014).   
 
 Proposed classification 
Until very recently, the classification of CD has been distinguished by HIV status alone.  
The frequent identification of HIV-negative, HHV-8 negative disease led some 
investigators to suggest that the HIV-based classification system was inadequate as it did 
not distinguish all the possible driving factors of CD pathogenesis (Ide et al., 2006; Naresh 
et al., 2009).  The newly proposed classification system states that the diagnosis of CD 
made primarily on the HHV-8 status is more appropriate, as it is thought to be more 
appropriate since it is linked to pathogenesis and treatment responses (Fajgenbaum et al., 
2014 ; Liu et al., 2016). 
 
1.4 Pathology 
 Hyaline vascular subtype 
HV-CD is characterised by lymphoid proliferation with frequently regressed lymphoid 
follicles, small atrophic germinal centres and widened mantle zones with small 
lymphocytes arranged concentrically in an “onion-skin” fashion (McCarty et al., 1995 ; 
Kojima et al., 2008).  The appearance of a single hyalinized blood vessel penetrating the 
follicle together with the concentric rimming by mantle zone lymphocytes is often 
described as resembling a ‘lollipop’ (Lin & Frizzera, 1997).  The interfollicular regions are 
often expanded with prominent hyalinised blood vessels, admixed myoid cells, dendritic 
reticulum cells and T- lymphocytes (Nyugen et al., 1994; Cronin & Warnke, 2009).  In 
addition, focally enlarged dysplastic follicular dendritic cell (FDC) networks are present.  
These follicular dendritic cells can sometimes be seen in aggregates within these expanded 
interfollicular zones (Harris & Bhan, 1987; Jegalian et al., 2009).  There is usually no 
observable increase in plasma cell infiltrates or eosinophilic aggregates and the lymph 
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node sinuses are often attenuated or closed (Nyugen et al., 1994).  The hypervascularity 
observed in HV-CD is thought to be driven by increased intrafollicular vascular 
endothelial growth factor (VEGF) expression (Bates & Harper, 2002).  Alterations in the 
follicular dendritic cell networks can eventually lead to neoplastic proliferations of 
dysplastic follicular dendritic cells with the eventual formation of follicular dendritic cell 
sarcoma, which is a rare malignancy that occurs more commonly in lymph nodes with 
HV-UCD (Chan et al., 1994; Cronin & Warnke, 2009).  This malignancy may also 
involve extranodal sites and can either be diagnosed concurrently with or following the 
diagnosis of UCD (Chan et al., 1997; Lin & Frizzera, 1997). 
 
 Plasma cell subtype 
Although the lymph nodes in PC-CD show less distinctive features than those seen in HV-
CD, there is usually preserved architecture with hyperplastic, rather than atrophic, 
lymphoid follicles (Nyugen et al., 1994).  These follicles contain larger and more active 
germinal centres that are surrounded by narrower mantles of mature lymphocytes with no 
associated expansion or abnormality of the FDC network (Cronin & Warnke, 2009).  The 
most striking feature of this subtype is the noticeable increase in interfollicular plasma cell 
infiltrates which are usually polyclonal in nature (Menke & DeWald, 2001).  These plasma 
cells may rarely be monoclonal, for example, in osteosclerotic myeloma, with associated λ 
light chain restriction (IgG or IgA) (Hall et al., 2006) and present with POEMS syndrome 
(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and/or skin 
changes) (Ohyashiki et al., 1994; Al-Maghrabi et al., 2006).  PC-CD like changes can also 
be seen in both reactive lymphadenopathies which include infections, autoimmune 
diseases, collagen vascular and mixed connective tissue diseases as well as in 
immunodeficiency-related lymphadenopathies (McClain et al., 2004; De Marchi et al., 
2004).  The multicentric form is almost exclusively of the plasma cell subtype and is 
frequently encountered in the immunosuppressed HIV-positive patient (Shahidi et al., 
1995; Cronin & Warnke, 2009).  It is often described in association with POEMS 
syndrome (polyneuropathy, organomegaly, monoclonal endocrinopathy, gammopathy and 
skin changes) (Ide et al., 2006). The unicentric form of PC-CD is probably the least well-
characterised subtype with many cases most likely representing a localised presentation of 
multicentric plasma cell CD (Cronin & Warnke, 2009). 
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 Plasmablastic subtype 
Another unique subtype exclusively associated with HIV is the plasmablastic subtype 
(Dupin et al., 2000; Ide et al., 2006; Naresh et al., 2009).  It is reported to be the most 
common subtype observed during HIV infection (Powles et al., 2007).  Most studies 
looking for viral particle sequences in these cases of HIV-MCD have shown high rates of 
HHV-8 infection (Stebbing et al., 2008; Naresh et al., 2008).  When localised, this type 
usually affects an aggregated mass of lymph nodes (Dupin et al., 2000).  It 
characteristically shows both plasma cell infiltrates in conjunction with an associated 
population of larger plasmablasts, the majority of which localise to the outer follicular 
mantle zones and paracortical regions.   
 
These plasmablasts are characterized by a moderate amount of amphophilic cytoplasm and 
large vesicular nuclei with 1–2 prominent nucleoli. They express OCT2, BLIMP1, and 
IRF4/MUM1, but lack positivity for PAX5, BCL6, CD138, and EBER (Dupin et al., 
2000). The plasmablasts express high levels of cytoplasmic IgM with monotypic λ light-
chain expression, but show a polyclonal pattern of immunoglobulin gene rearrangement 
(Du et al., 2001; Chadburn et al., 2008).  They can even show weak, variable expression 
of CD20 (Dupin et al., 1999; Chadburn et al., 2008; Naresh et al., 2009).  
 
 HHV-8 appears to also target IgM monotypic lymphocytes in the mantle zone of 
lymphoid follicles, which do not have somatic hypermutation of IgH chain genes, which 
indicates that these cells are derived from naïve B-lymphocytes.  These cells are often 
immature B-cells that have not undergone the germinal centre activation required for 
normal B-lymphocyte maturation (Du et al., 2001).  Dupin et al. (2000) have also 
demonstrated that HHV-8 is also able to infect B cells with plasmacytic differentiation, in 
both the mantle zones as well as in the interfollicular regions.  As the majority of these 
cells are HHV-8 infected, immunohistochemical staining with the monoclonal antibody 
directed against HHV-8 LANA-1, can be used to confirm these virally infected 
plasmablasts (Parravicini et al., 1997; Dupin et al., 2000; El-Osta & Kurzrock, 2011).   
 
Schulz (2006) demonstrated that up to 50% of the B cells within the mantle zones of the 
affected lymph node can show positive LANA-1 staining.  Although these plasmablasts 
mainly aggregate within the outer follicular mantle zones, they can eventually colonize the 
germinal centres (Cronin & Warnke, 2009).  Over time and within a background of 
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immunosuppression and HHV-8 infection, these plasmablasts can undergo clonal 
expansion with the resultant development of “microlymphomas’’ (Dupin et al., 2000; 
Stebbing et al., 2008).  These lesions can eventually progress to a plasmablastic 
lymphoma (Li et al., 2006). vIL-6, encoded by HHV-8 and also expressed in the infected 
plasmablasts, is responsible for driving malignant lymphoproliferation (Parravicini et al., 
1997; Aoki et al., 1999).  HHV-8-positive plasmablastic lymphoma is now regarded as a 
distinct entity arising in a background of HHV-8-associated MCD (Cronin & Warnke, 
2009).  These lymphomas are distinguished from other classic plasmablastic lymphomas 
arising in other settings due to the fact that the neoplastic cell population is genetically 
distinct, having arisen from naïve, IgM-producing plasma cells without immunoglobulin 
hypermutation (Dupin et al., 2000; Li et al., 2006).   
 
Du et al. also demonstrated that plasmablasts coinfected with both HHV-8 and EBV can 
sometimes exist in lymph nodes showing morphologically similar features to HHV-8- 
associated MCD (Du et al., 2001). These rare cases were subsequently referred to as 
‘Kaposi Sarcoma-associated Herpes Virus-associated Germinotropic Lymphoproliferative 
Disorder’ (Cronin & Warnke, 2009).  
 
 Mixed subtype 
The mixed subtype of CD shares morphological features of the hyaline vascular subtype 
and plasma cell subtype.  It is classically encountered in MCD and is typically seen in 
HIV-associated MCD (Gaba et al., 1978; Weisenburger et al., 1985). 
 
 Idiopathic multicentric Castleman Disease 
Although the role of HHV-8 in the pathogenesis of HIV-positive MCD is clearly defined, 
its role, if any, in HIV-negative disease remains controversial and for many cases of MCD 
that are negative for HHV-8, the aetiology still remains unclear.  As a result, these HIV-
negative, HHV-8 negative cases have been collectively classified as idiopathic MCD 
(iMCD) (Fajgenbaum et al., 2014; Liu et al., 2016).   
 
As iMCD patients also exhibit high cytokine levels, with IL-6 playing a central pathogenic 
role, Fajgenbaum et al. (2014) propose that iMCD most likely represents a common 
endpoint for multiple immunological processes that primarily involves immune 
dysregulation.  Some of the postulated mechanisms for iMCD include autoinflammatory 
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hypercytokinaemia generated by autoantibodies, abnormal cytokine secretion by affected 
cells within the lymph nodes or viral signalling by non-HHV-8 viruses (Fajgenbaum et al., 
2014). 
 
 Clinical and pathological features of iMCD 
In the past, the diagnosis was made primarily on “Castleman lymph node 
histopathological features” combined with thorough clinical correlation that excluded all 
other infectious, autoimmune and neoplastic diseases (Fajgenbaum et al., 2014). 
 
The proposal is that iMCD cases should have negative HIV serology, show no detectable 
replicating HHV-8 virus in the peripheral blood and have negative staining for LANA-1 in 
lymph node tissue (Fajgenbaum et al., 2014).  The absence of LANA-1 is key to the 
diagnosis Diagnostic criteria by the French Agence Nationale de Recherchesurle SIDA 
(ANRS) and the National Cancer Institute (NCI) proposed for patients with iMCD proved 
to be helpful (Gerard et al., 2007; Uldrick et al., 2012). This is due to the fact that 
histopathological diagnosis in HIV/HHV-8 associated MCD is made much easier by the 
complementary use of DNA tests to detect the presence of HHV-8 in the peripheral blood 
and positive LANA-1 immunostaining (Bower, 2010). Like HHV-8 associated MCD, 
iMCD can also show features of both hyaline vascular and plasma cell subtypes.  
However, iMCD generally presents with marked plasmacytosis and a lesser degree of 
vascular proliferation and hyalinisation, in comparison to HHV-8 associated MCD (Suda 
et al., 2001). 
 
There is often significant overlap with malignant, autoimmune, and infectious disorders 
which makes accurate diagnosis challenging. Until recently there were no standardised 
diagnostic criteria or diagnostic biomarkers. Fajgenbaum et al. (2016) published seminal 
consensus criteria for Castleman Disease diagnosis, with special reference to iMCD cases. 
These include major criteria (characteristic lymph node histopathology and multicentric 
lymphadenopathy), at least 2 of 11 minor criteria with at least 1 laboratory abnormality. 
Importantly, infectious, malignant, and autoimmune disorders that can mimic iMCD need 
to be excluded.  
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1.5 Epidemiology of unicentric (UCD) and multicentric (MCD) 
Since the discovery of HIV over three decades ago, the prevalence of CD has 
progressively increased. The prevalence in the United States was estimated to be less than 
1/100 000 (Degot et al., 2009).  Recent estimates suggest the incidence of all subtypes of 
CD (UCD, HHV-8-associated MCD and iMCD) to be approximately 6,500 to 7,700 new 
cases per year in the USA (Munshi et al., 2015).  The global incidence of MCD is 4.3/10 
000 patient-years (Oksenhendler et al., 2002; Powles et al., 2009).  There is no observable 
racial or ethnic predilection (Aguilar-Rodriguez et al., 2014).  There have been no formal 
studies with regards to incidence or prevalence of CD in South Africa.  There have, 
however been a few case reports and small case series from centres in South Africa, such 
as a series of 35 adult patients with MCD, who were seen over a twenty-five year period at 
Chris Hani Baragwanath hospital (Patel et al., 2015).  The average survival for UCD is 
greater than 10 years with an overall 5-year survival rate of 90%.  The mortality rate of 
MCD approaches 35% and is worse than both prostate and breast cancer (Munshi et al., 
2015).  The 5-year overall survival was 65% in 2012 series of MCD cases, while the 3-
year disease-free survival was reported at 46% (Talat & Schulte, 2011; Dispenzieri et al., 
2012). 
 
CD is very rarely reported in children and is predominantly diagnosed during the teenage 
years with a slight predilection of girls (Parez et al., 1999).  The majority of these 
childhood cases belong to the hyaline vascular type (Soumerai et al., 2014), which usually 
presents in a unicentric manner with a relatively asymptomatic course, the majority of 
symptoms being due to local mass effect.  There are only about 100 paediatric cases 
published.  MCD is rare in children with only few cases reported to date, but follows a 
more favourable course compared to adults (Parez et al., 1999).  Leroy et al. (2012) 
conducted a systematic literature review and found that almost half of the cases of 
paediatric MCD originated from areas in which HHV-8 is endemic. 
 
The classic HV-CD usually presents unicentrically and is found in 90% of UCD 
(Waterston & Bower, 2004; Collins et al., 2006).  It presents as a localised mass, most 
frequently occurring in a lymph node although extranodal presentations can also occur 
(Cronin & Warnke, 2009).  There is usually an absence of systemic signs and symptoms 
which are more commonly associated with MCD (Dispenzieri et al., 2012).  UCD most 
often presents in the third and fourth decades of life with the average age at diagnosis 
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being 34 years (range: 2–84 years) (Soumerai et al., 2014).  Although some studies have 
shown that there is a slight female predominance (1.4:1) (Talat et al., 2012), other series 
have shown no sex predilection (Keller et al., 1972; Herrada et al., 1998).  There is often 
no identifiable association with HIV or HHV-8 infection and definite epidemiological risk 
factors have not been established (Mylona et al., 2008).  If it is seen in the HIV-infected 
patient, it usually also co-exists with the plasma cell subtype, either within the same node 
or in a different node (Stebbing et al., 2008).  
 
Unicentric PC-CD accounts for 9% to 24% of localised CD (Keller et al., 1972; Frizerra, 
1988; Menke et al., 1996) and 80-90% of MCD (Waterston & Bower, 2004; Collins et al., 
2006).  Localised PC-CD shows a relatively similar sex and age distribution to the hyaline 
vascular subtype (Frizerra, 1988; Menke et al., 1996; Cronin & Warnke, 2009). Clinically, 
PC-UCD usually involves an aggregated mass of enlarged nodes as opposed to a dominant 
single node involved in HV-CD (Cronin & Warnke, 2009).  However even when 
localised, the unicentric plasma cell subtype is more likely to be associated with increased 
Il-6 serum levels, abnormal laboratory findings and systemic symptoms documented in the 
multicentric presentations (Flendrig & Schillings, 1969; Frizerra, 1988; Menke et al., 
1996; Casper, 2005).   The difference, though, is that unlike multicentric PC-CD which 
requires systemic therapy, surgical excision is reportedly curative in unicentric PC-CD 
(Brandt et al., 1990).  Multicentric PC-CD has been reported to present in the sixth decade 
of life (Frizzera et al., 1985; Herrada et al., 1998). Patients with HIV-associated MCD 
(both plasma cell and plasmablastic subtypes) however, although showing no age or sex 
predilection, tend to present at younger age with a slight male predominance (Al-Natour et 
al., 2010; Bower et al., 2011., Soumerai et al., 2014). 
 
Studies have also revealed an increased incidence of HIV-associated MCD since the 
introduction of antiretroviral therapy (Mylona et al., 2008; Soumerai et al., 2014).  The 
exact mechanism for this is unclear.  It may be attributed to longstanding immune 
dysregulation associated with long-term HIV infection, improved survival rates or even an 
increased awareness of the disease among treating health care professionals (Soumerai et 
al., 2014).  In contrast, there is a decreasing incidence of Kaposi sarcoma (KS) observed in 
patients enrolled on HAART (Powles et al., 2009). 
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1.6 Pathogenesis of CD  
Current knowledge regarding the aetiopathogenesis of CD is based largely on case series 
and histopathologic reviews accumulated over the last decadeClinical and laboratory 
investigations of patients with the different CD subtypes have enabled a greater 
understanding of the pathophysiology and management of CD.  Although CD was 
discovered more than fifty years ago, its exact pathophysiologic basis had not been fully 
elucidated.  The valuable information gathered from both clinical and pathological series 
of patients with CD led early investigators to identify elevated levels of IL-6 often driven 
by HHV-8, in the absence of other initiating factors. The abnormally high levels of IL-6 
serves as the triggering factor for the iniation of pathological processes within a defective 
immune system, eventually leading to lymphoid proliferation, angiogenesis and systemic 
manifestations characteristic of MCD.  Plasmablastic MCD was rarely identified early in 
the HIV pandemic and it received little attention until the finding of HHV-8 infected 
plasmablasts (Dupin et al., 1999; Dupin et al., 2000). 
 
 Human Herpes virus 8 
Early studies initially focused on isolating EBV-DNA within lymph nodes from patients 
diagnosed with CD to determine if EBV was the causative agent (Castleman et al., 1956; 
Keller et al., 1972).  Despite occasional CD cases showing EBV-DNA, its rare presence 
did not prove causation and these small studies eventually argued against EBV as the 
aetiological agent (Murray et al., 1995).  The 1994 discovery of the gamma-herpesvirus in 
KS tissue samples had an enormous impact on virology as it was found to be the causative 
factor for all forms of KS (Chang et al., 1994).  As KS had also been frequently reported 
in patients with MCD, these findings led researchers to investigate the link between HHV-
8 infection and CD (Soulier et al., 1995a/b).   
 
Since HIV is also highly replicated within lymphoid tissue, it was also considered to 
potentially play a role in the pathogenesis of the disease (Collins et al., 2006).  The 
pathogenesis of HIV-associated CD was then found to involve an interplay between the 
two viruses, HHV-8 and HIV, cytokines such as IL-6 and growth factors such as VEGF 
(Oksenhendler et al., 2000).  The relationship between HHV-8 and MCD has been 
extensively studied in the context of HIV infection (Soulier et al., 1995a).  Soulier et al. 
(1995b) also demonstrated that HHV-8 sequences were detected in lymph nodes in 100% 
of cases of HIV-associated MCD, compared to only 41% of cases with HIV-negative 
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MCD while other studies have confirmed an almost universal association of HHV-8 with 
HIV-associated MCD (Bower et al., 2011).  The overall conclusion of these studies was 
that HHV-8 negative CD did not exist in HIV-positive patients.  
 
 History of HHV-8 
Before the discovery of HHV-8 using molecular techniques almost all viruses had been 
identified using conventional virus isolation methods with cell cultures.  Chang et al. 
(1994) identified DNA fragments of the virus in KS tissues and used a representational 
difference assay, a subtraction PCR-based method, to show the presence of these unique 
herpes viral DNA sequences.  HHV-8 thus, became the first virus whose fragments were 
identified directly by the PCR method before any cell culture methods.   
 
When KS was identified in 1872 by Moritz Kaposi, it was considered a rare cancer, 
affecting mostly elderly men of Mediterranean descent (termed Classical KS) (Kaposi, 
1872).  In the early to mid-1980s, new cases of KS were observed in young men who 
showed none of the previous risk factors for KS and were later found to be AIDS patients.  
At the time it was not understood whether HIV was involved in the development of KS 
but the cancer was listed as one of the defining illnesses of AIDS.  It was only after the 
findings of Chang and associates that it was understood that KS resulted from a co-
infection in these patients with both HIV and HHV-8 (Chang et al., 1994).  Since then 
HHV-8 has also been identified in transplantation related KS (Hengge et al., 2002a).  Over 
the 23 years since the discovery of HHV-8, it has been established as an oncogenic virus 
with lymphotrophic, oncogenic properties. The oncogenic properties of HHV-8 and the 
fact that it has been aetiologically linked to two B cell malignancies, primary effusion 
lymphoma (PEL) and HHV-8+ plasmablastic lymphoma (Hengge et al., 2002b), has led to 
its classification as a class I carcinogen by the International Agency for Research on 
Cancer (IARC) (Gramolelli & Schulz, 2015). 
 
 Epidemiology and molecular characteristics of HHV-8 
Epidemiological studies suggest that HHV-8 has existed in the human population for at 
least a few centuries (Dukers & Rezza, 2003) and serological studies have revealed that 
HHV-8 infected individuals are found all over the world with seroprevalence of infection 
differing according to regions and countries.   More than 50% of HHV-8 seropositivity is 
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found in sub-Saharan Africa, 10-30% in Mediterranean regions and less than 10% in 
America, Asia and Northern Europe (Katano et al., 2000a). 
 
Phylogenetic analysis has revealed several distinct subtypes, which are believed to have 
diverged at least 10 000 years ago.  HHV-8 is the most recently identified human 
oncogenic herpesvirus expressing viral oncogenes which constitutively activate growth-
signalling pathways (Hengge et al., 2002a; Verma & Robertson, 2003).  HHV-8 is most 
closely related to Rhesus Rhadinovirus (RRV), while its nearest human herpesvirus 
relative is Epstein-Barr virus (EBV, HHV-4) (Alba` et al., 2001).  Like other 
herpesviruses, the HHV-8 genome consists of linear, double-stranded DNA (170 kbp) 
with a long unique region (LUR) and terminal repeats (TRs) at both termini (Russo et al., 
1996). The HHV-8 LUR is responsible for encoding at least 80 viral proteins and 12 pre-
microRNAs (miRNAs) (Cai et al., 2005). These in turn yield at least 25 miRNAs during 
viral latency, 18 of which are elaborated during this latency period (Liu et al., 2012).   
 
Like other herpesviruses, viral genes are categorized into lytic and latent genes, and also 
into immediate-early (IE), early (E), and late (L) genes based on their expressions. While 
all human herpesviruses share considerable homology, with many genes conserved 
amongst herpesviruses, HHV-8 also contains at least 15 distinct genes unique to itself 
which have been designated with the prefix “K” (Hengge et al., 2002a).  Genotyping of 
HHV-8 is based on catergorising the sequences of the hypervariable regions in its K1 gene 
(Zong et al., 1999). The HHV-8 K1 is classified into 5 genotypes: A, B, C, D and E with 
no correlation between genotype and HHV-8 related diseases (Zong et al., 1999).  
 
Some HHV-8-encoded genes are homologous to human oncogenes or cell-cycle 
associated genes while some are transformational genes, able to transform human cells and 
destabilise cellular responses to HHV-8 (Russo et al., 1996; Cesarman., 2014).  However, 
the expression of these viral encoded genes is severely restricted with only a few viral 
genes being expressed in HHV-8 infected cells.     
 
In more than 90% of infected tumour cells, HHV-8 is locked into a latent state and only 
asubset (1–5%) of the infected cells undergo lytic replication (Verma & Robertson, 2003; 
Dittmer et al., 1998).  Protein expression is therefore restricted to only a few viral genes.  
The majority of viral proteins are expressed only during active viral replication and only a 
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few in the early stages of non-productive infections (Russo et al., 1996).  Only six protein 
products have been shown to be associated with the persistent or latent stage of the viral 
life cycle and are encoded by a latency-associated gene cluster.  This cluster includes 
LANA-1 (Latency-associated nuclear antigen-1, ORF 73), viral cyclin/v-cyclin (ORF72), 
viral FLICE-inhibitory protein (K13, v-FLIP), kaposin (K12) and viral interferon 
regulatory factor-3 (vIRF-3, LANA-2), and short ORF K11.1 encoding vIRF-2 (Dittmer et 
al., 1998).   
 
The viral gene expression profile appears to differ among HHV-8 infected disorders.  
Lytic virus expression, including vIL-6, is most common in MCD, to a lesser extent in KS 
and relatively uncommon in PEL (Paraviccini et al., 1997; Kaplan, 2013).  Recently, 
luciferase immunoprecipitation system (LIPS), which is a liquid-phase immunoassay that 
uses a light emitting protein to quantitatively measure HHV-8 antibody levels, has been 
employed to diagnose infection. One such LIPS study that assesses the serum levels of 
latent and lytic HHV-8 antigens, detected significant differences in patients with KS and 
MCD (Burbelo et al., 2010).  
 
HHV-8 shares 30–50% homology to EBV and similar to EBV, it can induce latent 
infection of peripheral blood lymphocytes, immortalise lymphocytes in vitro, and lead to 
the development of malignant lymphomas (Hengge et al., 2002b).  Like other 
herpesviruses, HHV-8 is also proficient at evading the immune system through its ability 
to use viral immunomodulators, many of which are homologues of human genes that 
interfere with the host immune response.  One of the ways in which HHV-8 evades the 
immune system is through encoding of proteins that alter the host immune response from 
Th1 to Th2, which is achieved partly by the action of vIL-6, inhibition of complement and 
down-regulation of the adaptive immune response (Eaton et al., 2010).   
 
1.6.1.2.1 LANA-1 
There are numerous HHV-8 genes that affect binding, cell growth, proliferation, 
inflammation and angiogenesis.  Most prominent among these genes is LANA-1 which is 
involved in episomal maintenance, acts as a transcriptional regulator and modifies 
expression of viral and cellular genes (Eaton et al., 2010).  LANA-1 transcription is shown 
to be under the control of the LANA promoter (LANAp) (Dittmer et al., 1998; Hengge et 
al., 2002b). Numerous studies have shown that LANA-1 is a multifunctional protein 
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always expressed in HHV-8 -infected cells both in vivo and in vitro and that latency is 
maintained in infected cells (Dupin et al., 1999; Kellam et al., 1999).  Thus it is evident 
that LANA-1 plays an important role in the pathogenesis of HHV-8 infection, with the 
most important function being the ability to establish and maintain latency in infected cells 
by tethering the viral DNA to the host chromosome via the TR sequences on the HHV-8 
genome (Ballestas et al., 1999). 
  
LANA-1 modulates various cellular pathways both positively and negatively to ultimately 
use the host replicative machinery to drive cell proliferation. LANA-1 is also involved in 
signal transduction within the affected cell which dysregulates important signalling 
pathways, especially those involved in oncogenesis (Cesarman, 2014). Viral infection 
usually results in a protective induction of p53 expression and p53-dependent apoptosis in 
the cell. Direct binding with LANA-1, however, downregulates the important tumour 
suppressor pathways regulated by p53 and Rb (Friborg et al., 1999). Binding of LANA-1 
to p53, not only inactivates cellular apoptosis, it also blocks the tumour suppressor’s 
ability to act as a transcriptional activator which allows for viral survival and maintenance 
of the latent viral episome (Cesarman & Knowles, 1999; Cesarman, 2014).  Studies have 
also demonstrated a role for LANA-1 in regulating HHV-8 reactivation, which involves 
modulation of the major Notch cellular signalling pathway (Verma & Robertson, 2003).  
Although LANA-1 is crucial to HHV-8 pathogenesis, it does not have any full 




This gene encodes a latent protein that inhibits p53-tumour suppressor pathways and 
promotes VEGF (Schulz & Cesarman, 2015).  It is expressed only in PEL cells and CD 
but not in KS cells (Rivas et al., 2001).  
 
1.6.1.2.3 Viral cyclin (vCYC)  
It is a homologue of cyclin D1which can inhibit p27/Kip1 and induce the cell-cycle to S-
phase (Fukumoto et al., 2011).  Viral cyclin is a latent protein that modulates the cell cycle 
and assists the virus in evading normal regulatory checkpoints which allows the infected 
cell to overcome cell cycle arrest (Moore et al., 1998). 
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1.6.1.2.4 vFLIP (ORF K13) 
vFLIP, also a latent protein, is the third of the LANA-promoter coding regions that 
prevents Fas-induced programmed cell death by interfering with the Fas/TNFR pathway 
and is homologous to the cellular FLICE/caspase 8 inhibitory proteins (cFLIPs), which 
can inhibit death receptor mediated apoptosis (Kaplan, 2013; Cesarman, 2014).  Cell 
survival is also promoted through vFLIP activation of NFκB (Chaudhary et al., 1999).  
This causes the activation of numerous cellular genes, including anti-apoptotic genes.  In 
addition, expression of vFLIP and kaposin-B may play a role in enhancing cytokine 
expression and together with VEGF, play an important role in the vascular proliferation 
seen in KS and CD (Kaplan, 2013). 
 
1.6.1.2.5 Kaposins  
Kaposins are encoded in a complex region of the HHV-8 genome that contains the small 
coding region (K12) which can potentially encode three proteins: Kaposin A, B, and C 
(Cesarman, 2014).  Kaposin B is thought to play a role in stabilisation of cytokine mRNA 
and may enhance cytokine release (Kaplan, 2013). 
 
 South African context 
Serological studies have revealed that HHV-8 infected individuals are found all over the 
world (Sitas et al., 1999).  The prevalence of HHV-8 infection varies among different 
geographic areas with higher prevalence in areas where HIV infection is widespread 
(Caselli et al., 2005).   
 
An estimated 44,247 new cases and 26,974 deaths of KS worldwide was reported in 2012. 
This data also shows 40,874 of new cases in less developed regions and 3,373 new cases 
in more developed regions. The African continent is disproportionately affected, where 
37,509 (85%) of all cases occur (Globocan: 2012).  Malope et al (2008) reported that up to 
48% of HIV-infected adults in South Africa also tested positive for HHV-8.  The 
distribution of HHV-8 infection amongst HIV risk groups mirrors the pattern of KS 
occurrence in HIV-infected individuals.  A high prevalence of KS has been reported in 
sub-Saharan Africa (Dukers & Rezza, 2003). One of the first and largest studies 
addressing survival in KS in HIV-infected paients by Bohlius et al (2014) found that the 
incidence of KS is significantly lower in patients on establised HAART.  Mohanlal and 
Pather (2015) recently conducted a retrospective cross-sectional study of KS patients at 
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Chris Hani Baragwanath Academic Hospital and reported that the mean age of patients 
was 37 years, the male/female ratio was 1.2:1 and the median CD4 count was 128 cells/ul.  
KS remains the most common neoplasm in HIV-infected patients and the relative risk of 
developing KS in AIDS is much higher than that for other immunosuppressed patient 
groups (Sitas et al., 2000; Albrecht et al., 2004).   
 
In one South African study, the seroprevalence of HHV-8 was relatively high compared 
with that in the United States and has been found to increase significantly and steadily 
from birth into adult life (Sitas et al., 1999).  Furthermore, there was lower seroprevalence 
of HHV-8 in Whites than in Blacks in South Africa.   
 
 HIV 
Immediately after HIV infects a cell, the virion RNA is copied into DNA and the proviral 
genome is transported into the nucleus for integration into the host cell genome (Aboul-ela 
et al., 1995). Once integrated into the host chromosomal machinery, the HIV virion is 
regulated by cellular transcription factors, as well as its own regulatory proteins.  HIV 
transcription is controlled primarily by tat (trans-activator protein), which is one of the 
first proteins to be expressed after infection occurs. Unlike other transcriptional factors 
that normally bind DNA proteins, Tat binds RNA proteins and recognises a specific 
sequence, TAR (Tat activating region), which is present on the HIV-1 RNA molecule that 
results in increased HIV-1 mRNA production (Frankel & Young, 1998).  It is also mainly 
responsible for elongation by RNA polymerase II. This elongation allows for synthesis of 
full-length transcripts and increases transcription initiation (Aboul-ela et al., 1995).  In the 
absence of Tat, initiation from the long terminal repeats (LTR) is efficient but 
transcription is impaired as the promoter engages poorly functioning polymerases that 
disengage too quickly from the DNA template (Karn and Stoltzfus., 2012).  Tat protein is 
involved in stimulating cellular proliferation, inhibition of apoptosis and also stimulates 
the expression of growth-promoting cytokines.  In addition, Tat has been shown to directly 
act as an angiogenic factor that can interact with the VEGF-receptor (Hengge et al., 
2002b). 
 
 HIV and HHV-8 interaction  
Studies show that the simultaneous intracellular presence of HHV-8 and HIV-1 causes 
upregulation and reciprocal gene expression (Huang et al., 2001).  It has been proposed 
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that HIV promotes and initiates progressive HHV-8 infection through at least two 
important paracrine mechanisms (i) by production of the Tat protein and (ii) by promoting 
cytokine production (Mocroft et al., 1998).  HHV-8 may also have a direct effect on HIV 
infection as demonstrated by the in vitro co-cultivation of HHV-8 infected B-cell lines 
with HIV-infected CD4 T-cells which resulted in a significant increase of HIV replication 
(Mercader et al., 2001).  Studies also suggest that LANA-1 cooperates with HIV Tat to 
cause activation of the HIV LTR promoter which supports the proposal that HHV-8 co-
infection promotes HIV propagation (Huang et al., 2001).  There is also increased 
susceptibility to HIV in natural targets such as T-lymphocytes as well as otherwise non-
permissive cells such as B-lymphocytes, which then allows for transmission of HIV 
infection to uninfected T-cells (Caselli et al., 2005).   
 
HIV-1 induced immunosuppression also plays an important role in the pathogenesis of 
HHV-8 associated cancer.  HIV infection stimulates HHV-8 replication and reactivation in 
latently infected cells (Merat et al., 2002).  HIV-1 Tat protein can also increase HHV-8-
encoded G-protein-coupled receptor signalling, which causes an increase of the HHV-8 
lytic biological cycle with accelerated tumourigenesis (Pati et al., 2003; Harrington et al., 
1997) 
 
 Cytokine factors 
 hIL-6 
In the search for a unifying factor in the pathogenesis of CD, IL-6 has emerged as this key 
factor.  Studies have shown that this multifunctional cytokine is central in the 
pathophysiology of all forms of CD and is closely linked with the deranged systemic 
manifestations of the disease.  The association between the systemic features of CD, 
especially the plasma cell subtype and a factor secreted by affected lymph nodes was 
recognized as early as 1989 (Yoshizaki et al., 1989).  These investigators also noted an 
elevated concentration of IL-6 in a patient with UCD, which normalized after lymph node 
excision.  This was also followed by a reduction in clinical and biological abnormalities.  
This correlates with observations that exacerbations of MCD in HIV-infected patients 
show high levels of HHV-8 viral load and human IL-6 (Uldrick et al., 2012; Polizzotto et 
al., 2012; Polizzotto et al., 2013).   
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IL-6 is a multifunctional, pleiotropic cytokine produced by various cells such as T-cells, 
B-cells, monocytes, fibroblasts, and endothelial cells (El-Osta & Kurzrock, 2011).  It is 
considered the most important disease mediator in MCD.  It binds to a membrane receptor 
and leads to gp130 dimerization, phosphorylation, and activation of receptor-associated 
kinases (Rossi et al., 2015).  IL-6 has multiple downstream effects that are involved 
primarily with regulating multiple cellular signalling pathways, mainly via the JAK/STAT 
pathway (Nishimoto & Kishimoto, 2006), which in turn leads to VEGF expression and 
signalling (El-Osta & Kurzrock, 2011).  
 
 It is also involved in the synthesis of acute-phase reactant proteins by the liver and 
associated with the development of constitutional symptoms accompanying many 
inflammatory diseases (Nishimoto & Kishimoto, 2006). Leger-Ravet et al (1991) 
demonstrated that germinal centres of CD lymph nodes produced large quantities of IL-6 
with the subsequent detection of IL-6 secretion by germinal centre B cells. IL-6 has a 
triple role in the disease process which involves induction and survival of B-cell 
proliferations, generation of inflammatory symptoms and increased secretion of VEGF 
resulting in subsequent increased angiogenesis and interfollicular plasma cells, all of 
which may contribute to the symptomatology observed in CD (Aoki et al., 1999; Nishi et 
al., 1999).  
 
IL-6 is emerging as both a biologically and prognostically important cytokine in many 
lymphoid malignancies as it can also function independently as an autocrine or paracrine 
growth factor in a variety of cancers (El-Osta & Kurzrock, 2011). 
 
 vIL-6 
Apart from germinal centre B-cells, another source of IL-6 production in CD is from 
HHV-8 infected cells.  The virus has been shown to produce a viral analogue of IL-6 (vIL-
6) and shares many of the biological activities of hIL-6 (Moore et al., 1996; Parravicini et 
al., 1997b).  Although vIL-6 can activate hIL-6 signalling pathways independently of IL-
6R, it has low affinity for IL-6R when compared with hIL-6 (Friborg et al., 1999).   
 
vIL-6 induces angiogenesis by VEGF expression using similar mechanisms as hIL-6 and 
can therefore cause further increase in expression of hIL-6, suggesting that ‘molecular 
mimicry’ is also an important factor in the pathogenesis and evolution of MCD (Aoki et 
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al., 1999).  It also stimulates the JAK/STAT pathway via STAT3 signalling which results 
in increased cell growth (Aoki et al., 2003). The rate of expression of vIL-6 is much 
higher in MCD than in KS (only 1–2% of cells express vIL-6) or primary effusion 
lymphoma (Cronin & Warnke, 2009). Various studies, using quantitative polymerase 
chain reaction in peripheral blood mononuclear cells and plasma, have shown that there is 
an association between high copy numbers of HHV-8 and increased plasma IL-6 levels, 
both of which correlate with disease exacerbations and symptom flares (Grandadam et al., 
1997; Oksenhendler et al., 2000).  vIL-6, which is also believed to be a key player 
responsible for B-cell proliferation, is also frequently expressed on LANA-1 positive cells 
and its expression has been reported to confer a worse prognosis (Parravicini et al., 1997).  
 
Paravicinni et al. (1997) further demonstrated, using specific double immunostaining in 
CD, that some lymphovascular endothelial cells showed co-expression of LANA-1 and 
vIL-6. It is can also be expressed by a significant proportion of latently infected cells in 
MCD.  In lymphoid cells, vIL-6 is expressed mainly around the follicles and within the 
follicular dendritic network (Talat & Schulte, 2011).  It was also shown that vIL-6 was 
likely to contribute to neoplastic lymphoproliferations (Parravicini et al., 1997).  Both 
hIL-6 and vIL-6 are sufficient to induce disease flares in HHV-8 associated MCD with the 
increased expression of other proinflammatory cytokines (Reddy & Mitsuyasu, 2011).   
 
 IL-1 and NFκB 
There are two distinct IL-1Rs: IL-1RI and IL-1RII (Gherardi et al., 1994).  IL-1 usually 
binds to IL-1RI, triggering a signalling cascade in the cytoplasm leading to the activation 
of I-NFκB kinase (IKK).  NFκB is released and enters the nucleus to turn on several genes 
that regulate cell functions, especially those encoding IL-1 and IL-6 (El-Osta et al., 2010).  
It is likely that IL-1 and IL-6 are both overexpressed in CD because of aberrant upstream 
regulation or due to upregulation of IL-1 that eventually leads to elaboration of IL-6 (El-
Osta & Kurzrock, 2011). 
 
 Growth factors  
 VEGF  
As previously described, especially with reference to the HV-CD, blood vessel 
proliferation is an important histologic component although the role of angiogenesis in the 
pathophysiology of CD has received less attention than IL-6.  Nishi & Maruyama (2000) 
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demonstrated that increased VEGF expression is present in the interfollicular areas of 
lymph nodes in patients with CD, with some patients even having elevated systemic 
VEGF levels.  VEGF was found to be strongly expressed in plasma cells in CD but rarely 
expressed in normal lymph nodes (Nishimoto et al., 2000).  Dysregulated IL-6 gene 
expression is considered to be a primary event that is related to paracrine VEGF 
production by plasma cells and variable vascular proliferation in lymph nodes (Chen et al., 
2009).  This was reinforced by Nishi & Maruyama (2000) who examined one patient with 
the unicentric PC-CD and one patient with MCD, both who had elevated levels of serum 
VEGF which then fell to normal levels after nodal resection and chemotherapy 
respectively. 
 
 Epithelial growth factor receptor (EGFR) 
EGFR has been a therapeutic target in the treatment of various cancers.  Sun et al. (2003) 
evaluated EGFR expression in follicular dendritic cells and surrounding perifollicular 
reticular cells in patients with CD and found EGFR expression in all 24 cases.  The 
significance of immunohistochemical overexpression of EGFR in relationship to 
therapeutic targeting is less clear than that for EGFR mutations (El-Osta & Kurzrock, 
2011). 
 
 B-cell populations  
CD20 is a phosphoprotein expressed on the surface of mature B lymphocytes.  Immature 
B-cells are abundant in the germinal centres of lymph nodes where they interact with 
antigen presenting follicular dendritic cells and follicular T-helper cells (Beltman et al., 
2011).  Dupin et al. (2000) demonstrated that lymph nodes from patients with HHV-8 
associated MCD harboured HHV-8 in plasmablasts localised in the mantle zone.  These 
plasmablasts were IgM restricted and also showed variable expression of CD20.  HHV-8 
infected plasmablasts can express CD20 as well as B-lymphocyte-induced maturation 
protein 1 (BLIMP1) (Naresh et al., 2009; Shulte and Talat, 2010).  Recent data by 
Knowlten et al. (2014) shows that HHV-8 infected B-cells display a polyfunctional 
cytokine profile within a background of increased IL-6, tumour necrosis factor (TNF), 
macrophage inhibitory protein-1 (MIP-1) and IL-8 which occurs after HHV-8 infection as 
well as in the blood of HIV/HHV-8 co-infected patients with KS.  Campbell et al. (2014) 
postulated that activated B-cells within a chemokine rich environment is an important 
trigger that drives endothelial cell proliferation in KS.   
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This mechanism could be responsible for the development of HHV-8 associated 
malignancies.  B-cells could also serve as a reservoir of latently infected HHV-8 cells as it 
has been reported that LANA-1 was detected in IgM+ B-cells of tonsil origin (Hassman et 
al., 2011).  B-cells, localised to the mantle zone of B-cell follicles, are also known to 
harbour the HHV-8 virus in individuals with KS, PEL, and MCD (Ambroziak et al., 1995; 
Cesarman & Knowles, 1999).  A study conducted by Chadburn et al. (2008) on 17 cases 
of HIV-positive MCD indicated that although HIV-positive MCD originated in pre-
terminally differentiated B-cells, it may in fact arise from extrafollicular B-cells. These 
cells were characterised by OCT2, cytoplasmic lambda immunoglobulin expression, 
variable B-cell marker expression, lack of CD138 and EBV negativity.    
 
Rituximab, an anti-CD20 antibody, is currently used in CD to induce lymphodepletion and 
subsequent decrease of IL-6 production, not only in HHV-8 positive patients but also in 
HHV-8 negative patients (El-Osta & Kurzrock, 2011).  This is supported by numerous 
case series and two open-labelled studies that have successfully used Rituximab (Bower, 
2010).  One study of 21 patients with newly diagnosed HIV-associated MCD reported a 
radiological response rate of 67% with the overall and disease-free survival rates at 2 years 
being 95% and 79%, respectively (Bower et al., 2007).  The second prospective study, 
which enrolled 24 HIV-positive MCD patients classified as chemotherapy dependent, 
showed that Rituximab induced a sustained remission of 1-year duration in 17 of 24 (71%) 
patients with a 92% 1-year overall survival (Gerard et al., 2007).  These findings support 
the dual role played by B lymphocytes in both disease pathogenesis and in providing a 
reservoir for HHV-8 activation.   
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Figure 1: HHV-8 interaction with B-cell populations (Knowlton et al., 2014) 
 
1.7 DC-SIGN 
Dendritic cell-specific intercellular adhesion molecule (ICAM)-grabbing non-integrin 
(DC-SIGN) is a mannose-specific C-type lectin expressed by dendritic cells.  C-type 
lectins are calcium-dependent carbohydrate-binding proteins with a wide range of 
biological functions, many of which are related to immunity (Soilleux, 2003).  DC-SIGN 
(CD209) is expressed on myeloid dendritic cells (DCs) in the dermis, mucosa, lymph 
nodes, lung and thymic T-lymphocytes (Soilleux, 2003).   
 
 Functions of DC-SIGN 
The diverse and specialised functions of DCs and its widespread distribution in the body 
play important roles in bridging of the two arms of the immune system to obtain a defence 
against foreign antigens.  The various types of DCs, namely myeloid dendritic cells 
(mDC), Langerhans cells (LC), skin dermal dendritic cells (DDC) and submucosal 
dendritic cells (SMDC) all have essential roles in both innate and adaptive immune 
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responses to primary and subsequent infections as well as the reactivation of chronic viral 
infections (Campbell et al., 2014).  They act during the innate immune response as 
specialised cells that survey and detect antigens of foreign microorganisms throughout the 
body which induces their ability to communicate with helper and effector lymphocytes 
thus bridging the innate and adaptive response (Campbell et al., 2014). 
 
In the course of dendritic cell life cycle, DC-SIGN has emerged as a prominent receptor 
on DCs that mediates many critical interactions, including antigen uptake and presentation 
and transendothelial migration to lymph nodes (Su et al., 2003).  DC-SIGN also binds to 
ICAM-3 on T-lymphocytes, thereby playing an important role in the activation of T-
lymphocytes (Soilleux, 2003).  DC-SIGN and other C-type lectins act as pathogen 
recognition receptors that alert macrophages and DCs to take up and process pathogens for 
antigen presentation to T-cells (Geijtenbeek et al., 2002). 
 
 
Figure 2: Structure of DC-SIGN. DC-SIGN, composed out of four domains: (A) 
cytoplasmic domain, (B) transmembrane domain, (C) 7 or 8 extracellular neck repeats and 
(D) carbohydrate recognition domain (Alen and Schols, 2012)  
 
 DC-SIGN and HIV 
DC-SIGN also plays a pivotal role in HIV-1 infection as a DC-specific HIV-1 binding 
protein.  It also enhances HIV-1 infection of T-cells (Geijtenbeek, et al., 2000; Lin et al., 
2003).  The tissue distribution of immature DCs maximizes its chance to be bound by 
incoming virions being deposited in mucosal surfaces (Su et al., 2003).  It is present at 
sites of first exposure to HIV, including mucosal tissues of the cervix, rectum and uterus.  
It is also expressed on macrophages of the lung alveoli, placenta, inflammatory lesions, 
and IL-13 activated, monocyte-derived macrophages (Soilleux, 2003).  The glycoprotein 
gp120 selectively binds to the cardohydrate recognition domain (CRD) of DC-SIGN with 
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high affinity and is also known to bind HIV for protracted periods (Su et al., 2003; 
Rappocciolo et al., 2008). 
 
HIV has exploited DC-SIGN to perpetuate its own pathogenic life cycle by exploiting DC 
migration through the body.  It does this by binding DC-SIGN on the surface of immature 
DC via gp120 and enhancing its maturation which allows the virus to target the CD4+ T-
cells (Soilleux, 2003).  Two types of DC-mediated HIV transmission have been proposed: 
trans-infection and cis-infection (Rappocciolo., 2006).  Trans-infection mediated by DCs 
can occur by two pathways: i) HIV transmission occurs across the infectious synapse 
whereby DCs transfer captured HIV to target CD4+ T-cells through cell-cell junctions 
known as infectious synapses which are formed by DC-SIGN; ii) HIV transmission occurs 
by an exocytic pathway that involves HIV-associated exosomes.  Exosome-associated 
HIV virions are likely to be transmitted to CD4+ T-cells through membrane binding and 
fusion.  Cis-infection mediated by DCs occurs when there is HIV infection of DCs after 
initial exposure with replication in DCs resulting in de novo production and long-term 
transmission of HIV (Karn and Stoltzfus., 2012). 
 
HIV most likely has evolved strategies to specifically exploit the use of the DC-SIGN in 
its trans-infection process.  This exploitation specifically involves the Nef viral gene 
whereby expression of this gene in DCs increases the number of DC-SIGN molecules on 
the cell surface (Su et al., 2003).  This enhanced cell surface expression of DC-SIGN is 
advantageous to the virus since this increases the binding affinity to T-cells and therefore 
increases the chance the virus has to find its receptors on T-cells. 
 
 DC-SIGN and HHV-8 
Several receptors in the extracellular matrix have been implicated in HHV-8 entry into 
different human cell types.  It has been demonstrated that DC-SIGN is a cellular receptor 
for HHV-8 (Rappocciolo et al., 2006a; Rappocciolo et al., 2008; Knowlton et al., 2014).  
In addition to its expression on monocyte-derived dendritic cells (MDDCs), DC-SIGN is 
also expressed on activated macrophages and B-cells (Soilleux et al., 2000; Rappocciolo 
et al., 2006; Rappocciolo et al., 2008;).  These cell types represent natural targets for 
HHV-8 in vivo.  Studies on the interactions between DC-SIGN and other viruses known to 
use DC-SIGN as an entry receptor, such as HIV, Ebola, hepatitis C and cytomegalovirus 
(CMV), have demonstrated that viral glycoproteins are the viral attachment proteins 
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responsible for binding to DC-SIGN, or its endothelial cell-expressed homologue, DC-
SIGNR (Geijtenbeek et al., 2000; Pohlmann et al., 2000; Lin et al., 2003).  The majority 
of these studies have demonstrated that viral glycoproteins with a high mannose glycan 
structure, like HHV-8, bind to DC-SIGN/DC-SIGNR (Anderluh et al., 2012).   
 
Establishment of HHV-8 infection requires two separate events at the surface of 
susceptible cells which includes binding to an attachment receptor which is followed by 
binding to entry receptors (Campbell et al., 2014).  Although Langerhans cells do not 
express the HHV-8 entry receptor DC-SIGN, they do express the HHV-8 attachment 
receptor HS on their surface, which the virus uses before entry into the cell (Soilleux & 
Coleman, 2001; Hengge et al., 2002b). Initially, the host immune system is able to control 
the infection, however following an immune compromising event, such as organ 
transplantation or HIV infection there is reduced cellular antiviral response against HHV-8 
which is worsened by abnormal cytokine elevations (Campbell et al., 2014).  Reports 
support that HHV-8 is capable of recognising multiple receptors on human host cells and 
that HHV-8 employs receptor flexibility to expand the range of cell types it infects while 
at the same time adapting to different immunological environments that it encounters in 
the host (Hengge et al., 2002a).   
 
Studies done by Angel et al. (2009) demonstrated that DC-SIGN expressing antigen 
presenting cells (APCs) were located in the medullary cords and lined the capsule and 
trabeculae of lymph nodes.  These DC-SIGN+ APCs were also consistently found 
scattered throughout the paracortex of all lymph nodes examined, where they tended to 
wrap around high endothelial venules.  The subcapsular APCs also extended along 
trabeculae radiating into the lymph node as well as the capsule.  APCs expressing a low 
level of DC-SIGN were scattered around the medullary cords and in the perifollicular zone 
of the paracortex.  Plasmacytoid DCs (pDC) are a lymphoid-lineage subset of APCs that 
produce extraordinary amounts of the antiviral protein, interferon α (IFN-α) in response to 
virus infection (Liu et al., 2013).  Although pDC do not express DC-SIGN, it is known 
that pDC precursors express DC-SIGN, indicating they could also be susceptible to HHV-
8 infection (Campbell et al., 2014).   
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 DC-SIGNR 
A homologue of DC-SIGN, termed DC-SIGNR (for DC-SIGN related) (CD209L) or L-
SIGN (for liver/lymph node-specific ICAM-3 grabbing non-integrin) exhibits and shares 
77% amino acid identity with DC-SIGN with the greatest areas of homology located 
within the C-type lectin domain and the neck region (Geijtenbeek et al., 2002).  DC-
SIGNR is expressed on endothelial cells in liver sinusoids, lymph node, gastrointestinal 
tract, and placenta (Soilleux, 2003).  Endothelial cells have been speculated to play a 
similar role to macrophages and DCs in antigen capture and clearance from the blood.  
DC-SIGNR, like DC-SIGN, binds preferentially to high-mannose oligosaccharides 
through a carbohydrate recognition domain in the C terminus (Pohlmann et al., 2000).  
Studies have found that DC-SIGNR functions similarly to DC-SIGN with regards to virus 
attachment and transmission, as might be expected given the high degree of homology 
between these molecules (Soilleux et al., 2000). 
 
1.8 HIV/HHV-8 -associated MCD  
The diagnosis is often easily made in the appropriate high risk setting and is usually 
consistent with an inflammatory process characterised by fevers, multifocal 
lymphadenopathy, hepatosplenomegaly, oedema, severe cytopaenia, high serum C-
reactive protein levels, elevated HHV-8 DNA levels in PBMCs, extreme plasmacytosis in 
lymph nodes or bone marrow, Kaposi sarcoma and haemophagocytic syndrome (Mylona 
et al., 2008).  Research has shown that the exacerbation of clinical symptoms in HIV 
infected patients with MCD was associated with large increases in the HHV-8 viral loads 
in their PBMCs (Grandadam et al., 1997; Oksenhendler et al., 2000; Collins et al., 2006).  
Plasma levels of HHV-8 DNA predict relapse rates in HIV-associated MCD (Stebbing et 
al., 2011). 
 
Patients with HIV-associated MCD are at an increased risk of developing non-Hodgkin 
lymphoma (NHL).  A prospective cohort study of 60 HIV-positive MCD patients found 
that these patients have a 15-fold increased risk of developing HHV-8 associated non-
Hodgkin lymphoma as compared with the general HIV-positive population (Oksenhendler 
et al, 2002).  Three developed primary effusion lymphoma, five developed extranodal high 
grade B-cell lymphomas and six were diagnosed with an aggressive plasmablastic 
lymphoma.  It was estimated from this series that the 2-year probability of developing 
NHL after MCD diagnosis was 24% and neither plasma HIV RNA level nor CD4 count 
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was predictive. There is also an observable increase in occurrence of KS in HIV-
associated CD patients and KS foci have been described in the lymph nodes of nearly two 
thirds of patients (Lachant et al., 1985; Oksenhendler et al., 1996; Naresh et al., 2008; 
Mylona et al., 2008).   
 
Large population studies have also revealed an increased incidence of HIV-associated CD 
since the introduction of HAART, which appears to have no effect on the progression of 
the disease (Stebbing et al., 2008; Pinto and Nunes, 2011).  However, a study of 84 CD 
patients by Mylona et al. (2008) showed that life expectancy in MCD appeared to have 
improved, with a mortality rate of 29% among patients receiving ART compared to a 
mortality rate of 75% among pre-ART patients.  Another significant finding in their study 
was that patients on ART treatment at the time of diagnosis of MCD had a better 
immunological profile and were less likely to have concurrent KS than those commencing 
ART after the diagnosis of MCD was made (Mylona et al., 2008).  The introduction of 
HAART has been associated with a reduction in the incidence of many HIV-associated 
malignancies including KS as it causes a decrease in HHV-8 viral replication and 
prolonged time to progression (Bower et al., 1999).     
 
1.9 Associated conditions  
There are a variety of related processes and other disease associations, some of which stem 
from the immune dysregulation that occurs while other conditions may be direct 
manifestations of the CD. 
 
 Kaposi sarcoma 
Kaposi sarcoma was first described by Moritz Kaposi in 1872 as "idiopathic multiple 
pigmented sarcomas of the skin" and was characterised by angioproliferative, tumour-like 
lesions usually developing first in the skin with eventual dissemination to multiple 
cutaneous sites, viscera and lymph nodes (Kaposi, 1872).  Although previously a 
relatively rare disease, it is now a global health problem because of its association with the 
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There are four clinically recognised KS types:  
i) Classical or sporadic KS was initially described as a slow growing, indolent tumour 
mostly developing in the extremities of elderly males of eastern and Mediterranean Europe 
(Kaposi, 1872) 
ii) Endemic KS is clinically more aggressive and predominantly seen in eastern and 
central sub-Saharan Africa before the AIDS epidemic.  This type is clinically similar to 
classical KS, but can also present with a more fulminant and fatal form in children 
(Dedicoat & Newton, 2003 ).  The childhood endemic KS subtype often involves lymph 
nodes with or without skin involvement.   
iii) Iatrogenic KS is often seen as a consequence of drug related immunosuppression 
following transplantation, and normally regresses upon immune reconstitution (Mendez & 
Paya, 2000).  
iv) AIDS-associated KS is the most frequent tumour diagnosed in the setting of HIV 
infection and the most aggressive form of KS with early dissemination in the skin and 
viscera (Levine, 1992; Pyakurel et al., 2006).  This type frequently resolves upon 
treatment of HIV by antiretroviral combination therapy and the resulting immune 
reconstitution. 
Although these four clinical forms differ with regard to geographic distribution, 
aggressiveness and localisation, all display common clinical features and are histologically 
indistinguishable (Gramolelli & Schulz, 2015). 
 
In the setting of MCD, recurrent cutaneous and nodal forms of KS have been reported, 
being present at diagnosis or subsequently developing in 75% of patients with HIV-
associated MCD and 13% of HIV-negative patients with MCD (Soulier et al., 1995a/b; 
Oksenhendler et al., 1996).  Circulating HHV-8 infected cells are hypothesised to enter the 
lymph node through afferent lymphatics with early KS usually localising within the 
subcapsular and trabecular sinuses while advanced KS is observed to efface the majority 
of the node (O’Leary et al., 2000).  There is infection of both nodal smooth muscle and 
endothelial cells which eventually become spindled in morphology (Brousset et al., 2001).  
With progressive infection, small foci of spindle cells eventually appear in the subcapsular 
space of the node and interestingly reflect the highest copy number of HHV-8 (O’Leary et 
al., 2000).  KS, within the context of HIV-associated MCD, is often characterised by 
microscopic involvement of lymph nodes and spleen.  
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Although the co-existence of these two diseases within the same tissue has been observed, 
there are few actual reports in the literature with only a few case series 
immunohistochemically evaluating the presence of the two lesions within the same tissue 
specimen (Abe et al., 2006; Naresh et al., 2008; Pinto & Nunes, 2011).  Naresh et al. 
(2008) investigated the co-existence of the two entities in 24 lymph nodes and five spleens 
in patients with HIV-associated MCD.   
 
Among the lymph node specimens, 63% had additional microscopic involvement by KS 
involving the capsule, trabeculae and hilar regions.  This group was compared to 20 lymph 
nodes of HIV positive patients without evidence of CD.  Only 25% of the second group 
showed microscopic involvement by KS, which was significantly lower than in the group 
with MCD.  Another study by Abe et al. (2006) reported a case of KS and MCD in a 
single lymph node from a HIV positive patient, where immunohistochemistry was used to 
demonstrate the differential expression of the viral proteins in the two lesions.  It was 
found that MCD showed expression of both lytic and latency phase genes of HHV-8 
within the cells of the mantle zone, while the neoplastic cells within the KS lesions were 
predominantly positive for latency protein LANA-1 (Abe et al., 2006).   
 
In another similar study by O’Leary et al. (2000) researchers looked at 16 patients with 
CD and examined the correlation between HHV-8 and lymph node angiogenesis.  Of the 
study sample, 43% showed positive HHV-8 staining with further detailed analysis 
confirming that the virus was identified in 10% of the B-lymphocytes. Other studies, like 
the one conducted by Brousset et al. (2001), used double staining to evaluate the 
expression LANA-1 and vIL-6 in cases of MCD and KS.  They observed that 
approximately one-third of the lymphoid cells were positive for both markers in MCD, 
confirming both lytic and latent phase gene expression within these cells. 
 
 Non-Hodgkin lymphoma  
Patients with MCD often develop secondary tumours, such as KS, NHL, Hodgkin 
lymphoma and plasmacytoma (Oksenhendler et al., 1996).  Talat and Schulte (2011) 
reported that NHL has been reported in <5% of HIV-negative CD compared to 20% in 
HIV-associated CD. Oskendhendler et al. (2002) found that the HIV viral load or CD4 
count was not predictive of the risk of developing NHL and their prospective study of 60 
patients with HIV-associated MCD found that 23% developed NHL while up to 50% 
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developed aggressive plasmablastic lymphoma over a median period of 20 months.  In 
addition, there are lymphomas that arise de novo in the setting of MCD, that are now 
recognized in the current World Health Organization classification as large B-cell 
lymphoma arising in HHV-8 associated MCD (Swerdlow et al., 2008). 
 
 POEMS and TAFRO 
MCD is often associated with autoimmune signs and symptoms and MCD patients often 
have some manifestations of POEMS syndrome (Dispenzieri, 2011; Muskardin et al., 
2012).  POEMS syndrome is a rare, devastating, multisystemic disease that occurs in the 
setting of a plasma cell dyscrasia. 
  
A few large case series have documented MCD in 11–24% of POEMS cases (Soubrier et 
al., 1994; Dispenzieri et al., 2003).  Enlargement of the lymph nodes and spleen in most 
patients with POEMS syndrome is mainly secondary to plasma cell type MCD.  In a 30-
year retrospective study, 37% of MCD patients had concurrent POEMS syndrome (Shin et 
al., 2011).  However, peripheral neuropathy and monoclonal paraprotein with or without 
other features of POEMS are only rarely seen in patients with HIV (Shin et al., 2011).   
 
IL-6 may cause immune dysregulation, leading to autoimmune phenomena, such as, 
autoimmune haemolytic anaemia, thrombocytopaenia, pure red cell aplasia, acquired 
factor VIII deficiency, systemic lupus erythematosus and myasthenia gravis (Reddy & 
Mitsuyasu, 2011).   
 
TAFRO syndrome is a recently described condition characterised by concurrent 
generalised lymphadenopathy showing MCD features, and a constellation of symptoms 
that include thrombocytopaenia, anasarca, fever, reticulin fibrosis and organomegaly 
(TAFRO). TAFRO syndrome usually occurs in the middle-aged and elderly with a median 
age of 56 years.  It has a female predilection (4:1) and is not associated with HHV-8, HIV 
or EBV (Kawabata et al., 2013). The distinct clinicopathological features suggest that the 
TAFRO syndrome may represent a distinct subtype of what is currently considered iMCD. 
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1.10 Treatment modalities  
  Unicentric disease 
The preferred management of UCD is complete surgical excision, which is curative in 
approximately 95% of patients and affords resolution of constitutional symptoms, if 
present (Keller et al., 1972).  Active surveillance and long-term follow-up is 
recommended because recurrences that occur as late as 11 years after incomplete resection 
have been reported (Chronowski et al., 2001).  UCD also responds to local ablation 
therapy in cases where patient or anatomical factors make surgical resection difficult 
(Talat & Schulte, 2011).  
 
  Multicentric disease 
Until recently, MCD was not considered an AIDS-related or AIDS-defining event, and 
was often managed with local surgery, irradiation and cortisteroids.  Cytotoxic therapy 
was reserved only for highly symptomatic patients with refractory disease.  Historically, 
the prognosis has been poor, with a median survival not exceeding 25 months 
(Oksenhendler et al., 1996; Oksenhendler, 2009).  However, the prognosis has improved 
recently with the use of HAART and advanced therapeutic algorithms (Van Rhee et al., 
2010).  
 
As MCD is almost always symptomatic, therapy is recommended.  A wide variety of 
treatment options are available, which includes supportive care.  Therapy is aimed at 
eradicating the underlying viral infections, modifying IL-6 cytokine dysregulation, 
reduction of proliferating B-cell populations, debulking of tumour mass and improving 
immunocompetency.  Options for therapy include antiviral and antiretroviral agents, 
rituximab, chemotherapy, monoclonal antibodies, immune modulators and corticosteroids 
(Bower, 2010).  Chemotherapy has evolved from single-agent (e.g. chlorambucil) to 
combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone – 
CHOP), to the current use of rituximab and etoposide (Gerard et al., 2007; Bower, 2010).  
The literature however shows that although there are some strong responses, these 
responses are incomplete or short lived (Kaplan, 2013). 
 
 HIV-positive/HHV-8 positive MCD 
The use of HAART to treat patients with HIV/AIDS has altered the natural history of HIV 
and has increased overall survival and reduced the progression rate to lymphoma, which is 
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10-20 times lower since the introduction of HAART (Oksenhendler, 2009).  Unlike early 
series in which median survival of MCD patients was about poor, overall survival with 
current targeted therapies exceeds 85% at 1 year and sustained responses are often seen 
(Uldrick et al., 2012).  Active lytic HHV-8 replication is highest in MCD and disease 
flares are usually associated with an increased HHV-8 viraemia.   
 
As the pathogenesis of MCD also reflects HHV-8 infection of B-cells in affected lymph 
nodes, the use of anti-CD20 monoclonal antibodies to eliminate these pathogenic cells can 
be used as a treatment option.  Rituximab therapy, either alone or in combination with 
chemotherapy (R-CHOP), appears to be a promising first line treatment for HIV-
associated MCD (Bower, 2010).  The role of Rituximab in the treatment of HIV-
associated MCD is supported by prospective and retrospective trials demonstrating 
sustained remissions (Powles et al., 2009; Bower et al., 2011).  It should be noted that 
patients with MCD and concurrent KS may experience significant progression of KS after 
rituximab therapy (Kaplan, 2013).   
 
The promising clinical efficacy exhibited by targeting IL-6 or IL-6R has subsequently 
shown that IL-6 is an important target in the treatment of CD and monoclonal antibodies 
(anti-IL-6 & anti-IL-6R), such as Siltuximab, have proven to be successful targeted 
therapy options.  The correlation between the degree of proliferation of HHV-8 and 
symptom severity and symptom regression after administration of antiviral agents 
provides evidence of the critical role of HHV-8 in CD. 
 
 HIV-negative /HHV-8-negative MCD 
Three main treatment strategies have been employed based on the current understanding 
of iMCD.  These include the specific use of anti-inflammatory and immunomodulatory 
therapies to assist in the elimination of cells responsible for hypercytokinaemia as well as 
monoclonal antibodies, such as Tocilizumab and Siltuximab, for the blockade of aberrant 
IL-6 signalling (Fajgenbaum et al., 2014).  Although both these mAbs have shown clinical 
activity in iMCD and are potential options for frontline therapy, they do require life-long 
administration and may not be effective in all patients.  For those patients that are anti-IL-
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The US Food and Drug Administration (FDA) has approved siltuximab for the treatment 
of patients with HIV negative, HHV-8 negative MCD, where it shows significant clinical 
activity, resulting in control of IL-6 dependent systemic symptoms and laboratory 
abnormalities (Kurzrock et al., 2013).  Although there was improvement in symptoms, 
such as, fever, fatigue, anaemia, lymphadenopathy and hypergammaglobulinaemia, 
remissions were not sustained and recurrences were observed (Kaplan, 2013).   
 
Conventional anti-inflammatory and immunosuppressive therapies are currently being 
used more frequently as some physicians are treating iMCD more like a systemic 
inflammatory disease (Liu et al., 2016).  Rituximab, which is a frequent first or second-
line therapy in iMCD, is only partially effective and typically does not provide long-term 
disease control.  
  
Cytotoxic lymphoma-based chemotherapies, such as CHOP can be effective in a 
proportion of severely ill iMCD patients by reducing a large number of cytokine-secreting 
cells, although relapses are common and side effects are significant.  Novel therapies 
targeting other cytokines and intracellular signalling pathways are also being investigated 
as possible therapeutic options. 
 
It is of relevance that iMCD treatment can cause or even increase susceptibility to 
secondary malignancies with haematological malignancies being diagnosed in an 
increased frequency within 2-years of iMCD diagnosis (Fajgenbaum et al., 2014).  
 
1.11 Study justification 
The exact prevalence and incidence of CD in South Africa and sub-Saharan Africa has not 
yet been established. The number of HIV/HHV-8 MCD cases diagnosed at GSH is 
increasing and it is my opinion that the high prevalence of HHV-8 in the Western Cape is 
directly associated with HIVrelated CD.  Although it occurs more frequently in HIV-
infected individuals than those without HIV infection, the poor prognosis and often fatal 
course, is not fully explained by the underlying HIV alone. There are still many 
unanswered questions related to viral biology, aetiopathogenic kinetics and cellular targets 
implicated in CD.  One of the main cellular targets common to both virues is DC-SIGN 
and its related DC-SIGNR. Our hypothesis is that both HIV and HHV-8 s manipulate DC-
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SIGN and DC-SIGNR to gain access into susceptible cells, which allows for both immune 
evasion and the development of abnormal lymphoproliferations observed in CD.  
 
1.12 Aims and Objectives 
To determine the role that DC-SIGN and DC-SIGNR play in HHV-8 infection of target 
cells by demonstrating their presence in LANA-1 positive cells. We also wanted to 
determine whether HHV-8 and HIV co-infection occurs in the same cells by identifying 
dual LANA-1 and p24 expressing cells in addition to verifying if it was B- and/or T-
lymphocytes that infected by HHV-8 by using CD20 and CD3. 
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CHAPTER 2:  
MATERIALS AND METHODS 
 
2.1 Ethics approval 
Ethics approval was obtained from the University of Cape Town, Faculty of Health 
Sciences Human Research Ethics Committee (Reference number 144/2012; see Appendix 
2). Scientific approval was obtained from the Department of Pathology Research 
Committee. 
The study was funded by the National Health Laboratory Service Research Trust. 
 
2.2 Study design 
This was a retrospective descriptive and analytic cross-sectional immunohistochemistry 
study. 
 
2.3 Sample selection 
An electronic SNOMED search of the DISA laboratory information system (LIS) database 
of the Division of Anatomical Pathology, National Health Laboratory Service, Groote 
Schuur Hospital (GSH) was performed to identify all cases of Castleman disease from 
2003 to 2013.  Inclusion criteria included all CD cases diagnosed during study period. 
Exclusion criteria included needle core biopsy specimens. Archived stained slides of the 
cases were retrieved and reviewed by the study investigators.  The diagnosis in each case 
was reviewed.  Other relevant information that was recorded onto Excel data speadsheet 
(Appendix 1) included: 
• Age and sex of patient 
• HIV status (positive, negative or unknown) 
• CD4 count 
• Concurrent HAART 
• Castleman disease subtype 
• Topographic lymph node region excised with specific descriptors (localised vs 
generalised lymphadenopathy) 
• Previous or concomitant diagnosis of Kaposi sarcoma or non-Hodgkin lymphoma 
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Data for most of the variables except for CD4 count and HIV status were obtained from 
the histology reports. The HIV status and CD4 counts, where available, were obtained 
from relevant serological investigations and CD4 reports available on the DISA LIS. 
 
During review of the haematoxylin and eosin (H&E) sections a suitable block of tumour 
tissue was selected for immunohistochemical staining. 
Formalin fixed paraffin wax embedded tissue (FFPE) blocks were then retrieved from the 
archives of the Division of Anatomical Pathology and 3μm sections were cut for 
immunohistochemistry. 
 
Cases were allocated study numbers and patients’ names and other identification details 
were removed 
  
2.3.1 Reliability of data 
Demographic data entered onto the DISA LIS were obtained from the requisition forms 
completed by the submitting clinical doctor at the time of lymph node excision. The 
reliability of data for this study is therefore dependent on the accurate submission of 
information supplied especially with regard to variables such as age, sex and biopsy 
topographic sites. The accuracy of data obtained from the DISA system is also reliant on 
data capturers who entered details from requisition forms. 
 
2.4 Morphological analysis 
To avoid bias, the morphological review was conducted without knowledge of the original 
diagnosis.  Cases showing atrophic hyalinised germinal centres, hypervascularisation and 
FDC prominence were classified as HV-CD.  Cases exhibiting hyperplastic germinal 
centres, profuse plasmacytosis that expanded the interfollicular zones and a population of 
larger cells, 
plasmablasts (plasmacytoid immunoblasts), that localized to the mantle zone or 
paracortical regions were classified as PC-CD.  These plasmablasts are at least twice the 
size of reactive mantle zone lymphocytes and are characterised by a moderate amount of 
amphophilic cytoplasm, large vesicular nucleus and one or two prominent nucleoli. PC-
CD cases showing larger aggregates of these ‘plasmablasts’ both within the mantle and 
interfollicular zones and expressing LANA-1 by immunohistochemistry were then further 
subclassified as plasmablastic CD (Pb-CD). For purposes of this study, cases that showed 
 
                                                                                                                                                 39 
a combination of both HV-CD and PC-CD features were classified as mixed CD.  All 




Table 1: Primary antibodies 
ANTIBODY CLONE CLONALITY DILUTION INCUBATION SUPPLIER CONTROLS 
HHV-8-
LANA (M) 





























(Key: M – mouse; RT – room temperature) 
 
Four monoclonal antibodies (mAbs) were used in this study (Table 1). 
Anti-LANA-1 is the mAb directed against the latent nuclear antigen-1 (LANA-1) which is 
encoded by HHV-8 ORF 73.  
 
Anti-p24 is the mAb directed against the extracellular domain of the HIV-1 viral core 
protein.  Anti-DC-SIGN (CD209) and anti-DC-SIGN related (CD299/CD209L) are mAbs 
targeting human cellular receptors on dendritic cells.   
 
2.5.2 Controls 
A negative reagent control, in which the primary antibody was replaced by phosphate 
buffered saline solution (PBS) and an appropriate positive tissue control were run 
simultaneously for each batch of staining. 
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2.6 Immunohistochemical methods 
 Immunohistochemistry – Single antibody method 
 
Table 2: Kits used for the IHC protocol 
KITS SUPPLIER 
Envision HRP System Labelled Polymer Anti-mouse Dako - CA, USA 
Envision G/2 Double Stain System (Rabbit/Mouse) Dako - CA, USA 
Liquid DAB + Substrate chromogen system Dako – CA, USA 
 
• Three micron tissue sections were cut from FFPE blocks, picked up onto Histobond 
slides (Marienfeld-Germany) and heat fixed on a hotplate at 60ºC for 10-15 minutes. 
• Sections were dewaxed through xylene, cleared in ethanol and rehydrated in water. 
• Endogenous peroxidase activity was blocked by treating the slides with a 3% hydrogen 
peroxide (H2O2) solution for 10 minutes. 
• Slides were washed well in water. 
• Antigen retrieval was performed by pressure-cooking slides in Tris-EDTA (pH9) for 1 
minute 30 seconds at full pressure. 
• The sections were allowed to cool for 10 minutes. 
• This was followed by washing in tap water. 
• Thereafter, slides were rinsed with PBS (pH 7.6) (Oxoid-Hampshire, England). 
• Non-specific binding was blocked by treating slides with a 5% goat serum solution 
(DAKO - Denmark). 
• Serum was then drained off and sections were incubated with primary antibody at 
room temperature at specified times and dilutions (Table 1). 
• The slides were then washed well with PBS. 
• This was followed by incubation with DAKO Envision labelled Polymer, HRP 
(DAKO- USA) for 30 minutes at room temperature. 
• Sections were washed well with PBS. 
• Positivity was developed by applying the chromogenic substrate 3,3 diaminobenzidine 
(DAB) (DAKO - USA) for 10 minutes. 
• Slides were washed in running tap water and counterstained with Mayers 
haematoxylin for approximately 3 minutes. 
 
                                                                                                                                                 41 
• After washing in running tap water, sections were blued in ammoniated water. 
• Finally, the slides were then dehydrated through alcohols, cleared with xylene and 
mounted with Entellan (MERCK- Germany). 
 
 Envision G/2 DoubleStain System (DAKO) Method (Table 2) 
• FFPE tissue sections were cut at 3µm and picked up onto Histobond slides 
(Marienfeld-Germany). 
• The slides were then dewaxed through xylene and cleared in alcohol, with a final 
thorough wash in running tap water. 
• Antigen retrieval was performed in a pressure cooker for 1 minute 30 seconds using 
Tris EDTA pH9 as the retrieval buffer. 
• A 3% H2O2 solution was used to remove endogenous peroxidase for 10 mins. 
• After washing in water the slides were rinsed in DAKO wash buffer (DAKO, 
Germany) for 5-10 mins. 
• This was followed by incubation in 5% goat serum for 10-15 mins. 
• The appropriate first primary antibody (Table 3) was then applied to each slide 
according to the dilutions and time specified (Table 1). 
• After rinsing slides in DAKO wash buffer, Polymer HRP was then applied and left for 
10-20 mins. 
• DAB was used as the chromogen and was left to develop for 10 mins. 
• A wash in DAKO wash buffer solution followed for 5-10 mins. 
• The doublestain block was put on slides for 3mins. 
• This was followed by incubation with the second primary antibody (Table 3) 
according to the recommended conditions (Table 1). 
• Slides were then rinsed with DAKO wash buffer. 
• Rabbit/Mouse (LINK) solution was added and incubated for 10-20 mins (Table 2) 
• The polymer alkaline phosphatase (AP solution) was applied to slides for 10-15 mins. 
• Permanent Red was used as the second chromogen (Table 3) and incubated for 10 
mins. 
• Slides were counterstained in haematoxylin for 3 mins 
• Finally, the slides were coverslipped using glycergel (DAKO, Germany) as the 
mounting medium. 
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2.7 Dual immunohistochemical staining profiles 
The dual immunoreactivity for each antibody pair, as listed below, was assessed. 
• DC-SIGN and LANA-1 
• DC-SIGNR and LANA-1 
• p24 and LANA-1 
• CD20 and LANA-1 
• CD3 and LANA-1  
 








LANA-1 and DC-SIGN  





Membranous (red signal) 
and nuclear (brown 
signal)  
LANA-1  and DC-
SIGNR                      
LANA-1 (DAB) DC-SIGNR 
(Permanent Red) 
Membranous (red signal) 
and nuclear (brown 
signal) 
LANA-1 and p24 p24 (DAB) LANA-1  
(Permanent Red) 
Nuclear (red signal) and 
membranous (brown 
signal)  
LANA-1 and CD20 or 
CD3 
LANA-1 (DAB) CD20 or CD3 
(Permanent Red) 
Nuclear (brown signal) 
and membranous (red 
signal) 
 
Positive LANA-1 staining was detected by a brown colour due to the chromogen used in 
all double staining immunohistochemical combinations, except LANA-1 and p24 (Table 
3).   
For the purposes of this study, the distribution (density as number of positive cells per 10 
hpf) and intensity (either weak or strong) of HHV-8 LANA-1 immunohistochemical 
staining was specified by the investigators. 
Weak staining has been defined as requiring examination under high magnification (x40 
objective). 
Strong staining has been defined as nuclear staining (multiple closely packed dots) visible 
at low magnification (x10 objective). 
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2.8 Immunohistochemical analysis 
All 50 cases were assessed for:  
• LANA-1 and DC-SIGN co-staining. 
• LANA-1 and DC-SIGNR co-staining. 
o Co-staining cells were manually counted and their location within lymph 
node documented i.e. follicle, mantle zone or sinuses.  
 
• LANA-1 positive cases were then scored for density of virally infected cells.  
o The total number of LANA-1 positive cells in 10 high power fields (HPF) 
was manually counted  
 
•  LANA-1 and p24 co-staining. 
o Co-staining cells were manually counted and their location within lymph 
node documented i.e. follicle, mantle zone or sinuses.  
 
• LANA-1 and CD20 and CD3 
o Co-staining cells were manually counted and their location within lymph 
node documented i.e. follicles, parafollicular or paracortical zones.  
 
All cases were assessed for concurrent Kaposi sarcoma. 
 
2.9 Statistical analysis 
Data used was determined by counting cellular staining patterns and quantifying by visual 
count on each slide per 10 high power fields. 
 
Descriptive data was presented as mean, median and ranges for the entire cohort and for 
specific categories that included age, use of HAART, CD4 count and Kaposi sarcoma. 
Statistical analysis of quantitative variables was done using ANOVA. A significance level 
of P <0.05 was deemed statistically significant for all statistical tests. 
 
If the ANOVA analysis was significant, the Dunn's multiple comparisons test was 
performed to determine specific statistical significance between groups.  Statistical 
analysis was done using STATA 14 and GraphPad Prism. Data was also visualised using 
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SAS (University Edition, Red hat, SA). Association between categorical variables was 
determined by using either a Chi squared test or a Fisher’s exact test as applicable.  A 
significance level of P <0.05 was deemed statistically significant for all statistical tests.  
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CHAPTER 3:  
RESULTS 
 
3.1 Study cases 
The specimen numbers of 65 cases of CD diagnosed over the study period were obtained 
from the LIS. Six cases that were diagnosed on needle core biopsies were excluded. 59 
tissue blocks were then retrieved from the Anatomical Pathology archives. An additional 9 
cases were later excluded due to damaged tissue blocks. A final total of 50 cases of CD 
were entered into the study. The number of cases diagnosed per year is shown in Figure 3. 
 
 
Figure 3: Number of cases of CD diagnosed at GSH from 2003 to 2013 (Jan-Jul) 
 
3.2 Morphological analysis  
The 50 cases in the cohort were originally diagnosed as 25 (50%) HV-CD cases, 16 (32%) 
PC-CD cases and 9 (18%) mixed subtypes cases.  None of the cases were originally 
diagnosed as plasmablastic subtype.  
  
 
















Figure 4: Castleman disease subtypes (A) Hyaline vascular (HV-CD) subtype with 
characteristic penetrating vessel. (B) Mixed-CD showing a combination of hyaline 
vascular and plasmacytic features. (C) Plasma cell (PC-CD) with plasmacytosis and 
occasional plasmablasts in the mantle zone (white arrows). (D) Plasmablastic (Pb-CD) 
with larger number of plasmablasts (40x obj magnification). (E) Kaposi sarcoma.  (F) 
LANA-1 positivity in spindle cells (20x obj magnification).  
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The histopathology of all the cases was re-evaluated. Specific morphological criteria 
included assessment of germinal centre regression, increased vascularity, FDC 
prominence, interfollicular plasmacytosis and the presence of plasmablasts.  On analysis, 
all cases satisfied the histopathological criteria for a diagnosis of CD, although there was 
some variation in morphological appearance.  The cases were re-classified by the 
investigators using the plasmablastic-CD as an additional subtype after morphologic and 
immunohistochemical analysis (Figure 5).  In total 29 cases were re-classified (Table 4 
and Figure 8).  
 
There was an observable increase in Pb-CD from 2006 (Figure 6 and Figure 7). After re-
analysis of the entire cohort, there were equal numbers of HV-CD and Pb-CD subtypes 
(n=16) and equal numbers of PC-CD and mixed-CD subtypes (n=9) (Figure 9).   
 
     
    
Figure 5: Density of LANA-1 staining (A) Hyaline vascular (HV-CD) subtype with 
characteristic penetrating vessels, atrophic hyalinised germinal centres, prominence of 
follicular dendritic cells and hypervascularity (B) Occasional LANA-1 positive cells (C) 
Plasmablastic (Pb-CD) with large numbers of plasmablasts with large vesicular nuclei and 
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Figure 6: Number of CD subtypes originally diagnosed (per year) 
 
 
Figure 7: Number of CD subtypes after morphological reclassification (per year) 
 
According to the morphological critera used, the two HV-CD cases that were re-classified 
as PC-CD showed a prominence of hyperplastic follicles, interfollicular plasmacytosis, 
presence of plasmablasts and an absence of distinctive vascularity. Four HV-CD cases 
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were further re-classified as Pb-CD after morphological analysis and 
immunohistochemical demonstration of LANA-1 positivity within these plasmablasts.     
 
Table 4: Overview of reclassified CD cases 
Original number of 
Castleman disease 
Number of 
reclassified cases  
HV PC Pb M 
HV-CD 
n = 24 
10 14 2 4 4 
PC-CD 
n =17 
12 0 5 9 3 
Mixed-CD 
n = 9 
7 2 2 3 2 
Total number  
n = 50 
29 16 (32%) 9 (18%) 16 (32%) 9 (18%) 
 
 
Figure 8: Breakdown of original and reclassified CD subtypes 
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Figure 9: Number of CD subtypes before and after morphological reclassification 
 
3.3 Age  
The cohort of patients included 26 men and 24 women ranging in age from 14 to 76 years 
(median 36 years). The median age for the total cohort was 36 years (mean 37.7 years, 
range 14-76 years).  HV-CD had a median age of 36.5 years (mean 37.8, range 14-76 
years).  PC-CD had a median age of 37 years (mean 38.6, range 23-61 years).  Mixed CD 
had a median age of 33 years (mean 35.1, range 23-56 years). There were no statistically 
significant differences when comparing age amongst hyaline vascular, plasma cell, 
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Figure 10: Age distribution amongst CD subtypes (including Pb-CD ♦)  
 
3.4 Sex distribution 
The cohort included 26 males and 24 female patients. This equates to a male: female ratio 
of 1.08:1. When assessing the sex ratio amongst the specific subtypes, the HV-CD was the 
only subtype that showed a female predominance (Table 5). 
 
Table 5: Male:Female ratio amongst reclassified CD subtypes 
 Males  Females Sex ratio 
Entire cohort 26 24 1.08:1 
HV-CD 6 10 0.6:1 
PC-CD 6 3 2:1 
Pb-CD 9 7 1.28:1 
Mixed-CD 5 4 1.25:1 
 
 Summary Adjusted 
P value 
Hyaline vascular  vs. Mixed  ns 0.8701 
Hyaline vascular vs. Plasma cell  ns 0.9735 
Mixed  vs. Plasma cell (including plasmablastic)  ns 0.7522 
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3.5 Race 
There were thirty-seven African (74%), eight Coloured (16%) and five White patients 
(10%) in the cohort.  
 
3.6 Lymph node status 
The lymph nodes were obtained from several different nodal regions.  Twenty-seven 
(54%) patients presented with localised lymph node enlargement.  Specified sites included 
14 cervical (52%), 10 axillary (37%), 2 inguinal (7%) and 1 mediastinal (4%) lymph 
nodes. The location of the excised lymph node in the setting of generalised 
lymphadenopathy (46%) was not specified in all cases but included lymph node excisions 
from the axilla, neck and inguinal region. There was, however, not enough clinical 
information to definitively subclassify each case as either UCD or MCD. 
 
3.7 HHV-8 status 
HHV-8 LANA-1 immunohistochemistry was performed on only 37 cases at the time of 
diagnosis (32 positive and 5 negative). After LANA-1 immunohistochemistry was 
repeated on all 50 cases, LANA-1 positivity was present in the 32 cases initially reported 
as being positive, 3 of the 5 cases that were initially reported as being LANA-1 negative 
and 5 of the 13 cases that were previously untested. Immunohistochemical analysis 
revealed that 80% (n=40) of the cohort were LANA-1 positive and 20% (n=10) were 
LANA-1 negative (Figure 11).  
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3.8 HIV status 
HIV positivity is significantly associated with HHV-8 positivity in this cohort by Chi-
squared test analysis. The Chi-square statistic is 22.22 (p-value = 0.000002) (Table 6). 
 
Table 6: HIV and HHV-8 distribution of cohort 
 
HIV + HIV - Row Totals 
HHV-8 + 40*   (36)**    [0.44]*** 0*   (4)**   [4]*** 40 
HHV-8 - 5*     (9)**      [1.78]*** 5*   (1)**   [16]*** 10 
Column Totals 45 5 50    (Grand Total) 
* number of observed cases; ** (number expected as per chi squared test); *** [ chi 
squared statistic] 
 
The cohort included 43 patients who were documented as being HIV positive (n=35) and HIV 
negative (n=8) using the clinical history provided on the requisition form or the recorded result of 
the ELISA test located on the DISA LIS, at the time of lymph node biopsy and diagnosis. The 
HIV-status was unknown in the remaining 7 patients.  Six of the 35 HIV-positive patients 
had plasma HIV viral loads less assay detection (ie <50 copies/uL).  HIV p24 IHC was 
performed on all the cases in the cohort. The original 35 reported HIV-positive cases, 3/8 
of the reported HIV-negative cases and all 7 HIV-status unknown cases showed positive 
p24 immunohistochemical staining.  After immunohistochemical evaluation of all 50 
cases, 45 (90%) of the patients were confirmed as being HIV positive while 5 (10%) were 
HIV-negative (Table 6). A comparison of CD subtype with HIV and HHV-8 status 
showed a that there was a predominance of male Black patients with Pb-CD within the 
HIV(+)/HHV-8(+) subgroup (Table 7). 
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Table 7: Comparison of CD type with Age and Sex 




















































Pb = 16 
HV = 7 


















3.9 CD4 counts and HAART 
The CD4 count was known in 26 of the confirmed 45 HIV infected patients (including the 
p24 positive cases). There was no statistically significant difference in CD4 counts 
amongst CD subtypes (p = 0.1631) (Figure 12).   
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Multiple comparisons test Summary  Adjusted P 
value 
Hyaline vascular type vs. Mixed type ns 0.9951 
Hyaline vascular type vs. Plasma cell type ns 0.4985 
Hyaline vascular type vs. Plasmablastic  ns 0.6398 
Mixed type vs. Plasma cell type ns 0.4427 
Mixed type vs. Plasmablastic ns 0.6361 
Plasma cell type vs. Plasmablastic ns 0.9883 
 
Figure 12: Comparison of CD4 counts amongst subtypes (including Pb-CD ♦) 
 
The CD4 counts of the 26 patients ranged from 37 to 879 x 106/l.  The mean CD4 count 
was 270 x 106/l (median 193 x 106/l). Thirteen of the 26 cases had CD4 counts <200 x 
106/l (mean 119 x 106/l, median 134 x 106/l). 
 
Twenty-two of the 26 patients with known CD4 counts received highly active 
antiretroviral therapy (HAART) prior to diagnosis of CD.  There was no information 
regarding length of time between HAART initiation and disease presentation. It is 
undetermined as to whether the remaining 4 patients with known CD4 counts were 
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initiated on HAART after the diagnosis was made.  Of the 22 patients already initiated on 
HAART, 14 (64%) (n=14) were classified as PC-CD (10 plasmablastic subtype), 3 (14%) 
as HV-CD and 5 (23%) as Mixed-CD.  Six of the 22 patients enrolled on HAART had 
plasma HIV viral loads less than the level of detection of assay (<400 copies/ul, depending 
on the assay used), 6 patients had viral loads > 400 copies/ul, while the remaining 10 
patients did not have documented viral loads.  The remaining 9 patients of the original 35 
patients who tested positive for HIV had neither documented CD4 counts nor clinical 
information regarding initiation of (HAART) prior to diagnosis.  
 
3.10 Concurrent Kaposi sarcoma 
Eight (16%) of the 50 cases (2 x HV-CD, 3 x PC-CD, 1 x Pb-CD and 2 x Mixed-CD) 
showed histological evidence of concurrent KS within the affected lymph node (Figure 13 
and Figure 14). 
 
Figure 13: Castleman disease and Kaposi sarcoma (A-B) Kaposi sarcoma within lymph 
node (C) Spindle cells and endothelial cells within KS (D) LANA-1 nuclear staining of the 
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Figure 14: Distribution of diagnosed CD subtypes with concurrent KS 
 
3.11 Localisation of DC-SIGN and DC-SIGNR within lymph nodes 
Cells expressing membranous DC-SIGN and DC-SIGNR were seen predominantly within 
the subcapsular sinuses, cortical sinuses, medullary sinuses and scattered within the 


























Figure 15: Lymph node localisation of DC-SIGN and DC-SIGNR (A) Normal localisation 
of DC-SIGN expressing cells within subcapsular and cortical sinuses (B) Normal 
localisation of DC-SIGNR expressing cells seen predominantly within lymphatic sinuses 
 
3.12 Localisation of p24 within lymph nodes 
HIV infected cells with brown membranous/cytoplasmic staining for p24, showed almost 
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Figure 16: Localisation of p24 within germinal centres and mantle zones. P24 staining of 
follicular dendritic cells (cytoplasmic /membranous brown) 
 
3.13 Location and density of LANA-1 positive cells amongst CD subtypes  
When evaluated for distribution of HHV-8 infected cells, the HV-CD subtype (n=16) 
showed focal (≤10% of cells showing nuclear staining) and weak (discrete dot-like nuclear 
stippling seen at high magnification) LANA-1 immunohistochemical staining.  
 
In contrast, when evaluated for HHV-8 infected cells the Pb-CD (n=16), PC-CD (n=9) and 
Mixed-CD (n=9) subtypes all showed a high density of cells showing dot-like nuclear 
staining (Figure 17 and  
Table 8).  
 
 




Figure 17: Density of LANA-1 cells (A) HV-CD with low numbers of LANA-1 staining 
cells (20x obj magnification) (B) Pb-CD with numerous LANA-1 staining cells (20x obj 
magnification) (C) Strong LANA-1 dot-like nuclear staining of plasmablasts (40x obj 
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Multiple comparisons test Summary  Adjusted P 
value 
Hyaline vascular  vs. Mixed  * 0.0291 
Hyaline vascular vs. Plasma cell  ns 0.0584 
Hyaline vascular vs. Plasmablastic  **** 0.0002 
Mixed  vs. Plasma cell  ns 0.9985 
Mixed vs. Plasmablastic **** 0.0002 
Plasma cell vs. Plasmablastic **** 0.0002 
   
Figure 18: Comparison of LANA-1 density amongst CD subtypes (including Pb CD ♦) 
 
Table 8: Density of LANA-1 cells  (per 10/hpf)  
 Mean Median Range 
HV-CD 9.96 5.95 19 
PC-CD 44.6 34.6 101 
Mixed-CD 47.4 44.7 129 
Pb-CD 111.56 99.25 165 
 
When comparing density of HHV-8 infected cells amongst the different subtypes, there 
was a statistically significant difference in density of HHV-8 infected cells between Pb-
CD and all the other subtypes ie. HV, Mixed- and PC-CD all with p = 0.0002 (Figure 18). 
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Figure 19: Co-localisation of LANA-1 and DC-SIGN/ DC-SIGNR within lymph nodes 
(A) Double immunohistochemical staining of Pb-CD subtype with LANA-1/DC-SIGN. 
LANA-1(nuclear brown) and DC-SIGN (membranous red) co-expressing cells can be seen 
within sinuses (B) Co-localising LANA-1 and DC-SIGNR within lymph node sinuses 
(20x obj magnification) 
 
All 50 of the CD cases were evaluated for HHV-8/DC-SIGN and HHV-8/DC-SIGNR co-
expressing cells.  The highest number of co-staining cells was observed in Pb-CD (mean = 
7.9; median = 6; range = 4 - 20) with localisation of these cells predominantly within the 
sinuses (Figure 19).  The least number of co-expressing cells were observed in HV-CD 
(mean = 1.6; median = 1.5; range = 0 – 4) (Table 9 and Table 10). There were 2 HV-CD 
cases that showed an absence of co-expressing cells.  
 
Table 9: Number of LANA-1/DC-SIGN co-staining cells amongst CD types  (per 10/hpf)  
 Mean  Median  Range 
HV-CD 1.6 1 4 
PC-CD 3.3 3 5 
Mixed-CD 4.3 4 3 
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Table 10: Number of LANA-1/ DC-SIGNR co-staining cells amongst CD types (per 
10/hpf) 
 Mean  Median  Range 
HV-CD 1.8 2 2 
PC-CD 2.8 2 4 
Mixed-CD 2.4 3 3 
Pb-CD 5.6 4 13 
 
The Pb-CD cases showed numerous LANA-1 positive cells within the subcapsular 
sinuses, medullary cords and intranodal sinuses with noticeable aggregation within 
follicles and germinal centres. It was predominantly within these specific locations that 
LANA-1/DC-SIGN and LANA-1/DC-SIGNR co-expressing cells were seen (Figure 19 
and Figure 20). 
  
 





Figure 20: Co-staining LANA-1/DC-SIGN (A) and DC-SIGNR (B). LANA-1 (nuclear 
brown) and DC-SIGN/DC-SIGNR (membranous red) co-expressing cells (40x obj 
magnification, inserts under oil magnification) 
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There was a statistically significant differences in the number of LANA-1/DC-SIGN co-
staining cells between HV-CD and Pb-CD (p = 0.0072) and HV-CD and PC-CD (p = 








Figure 21: Comparison of co-staining LANA-1/DC-SIGN cells amongst CD subtypes 
(including Pb-CD ♦) 
 
3.15 LANA-1 and p24 
Dual staining LANA-1/p24 cells were identified (Figure 22) with more of these cells seen 
in Pb-CD (Table 11).  There was a statistically significant difference in the number of co-
expressing cells between the Pb-CD and HV-CD (p < 0.0001) (Figure 23). There were 
Multiple comparisons test Summary  Adjusted P 
value 
Hyaline vascular  vs. Mixed  ns 0.5616 
Hyaline vascular  vs. Plasma cell  * 0.0458 
Hyaline vascular type vs. Plasmablastic  ** 0.0072 
Mixed  vs. Plasma cell  ns 0.5182 
Mixed  vs. Plasmablastic ns 0.1269 
Plasma cell  vs. Plasmablastic ns 0.6178 
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also statistical differences observed between HV-CD and Mixed-CD (p = 0.0007) as well 
as PC-CD and Pb-CD (p = 0.001) (Figure 23). 
               
 
Figure 22: Double immunohistochemical staining with LANA-1 and p24. LANA-1 
(nuclear red) and p24 (cytoplasmic brown) co-expressing cells (40x obj magnification and 
under oil) 
 





Figure 23: Comparison of co-staining LANA-1 and p24 cells amongst CD subtypes 
(including Pb-CD ♦) 
 
Table 11: Number of co-expressing LANA-1 and p24 cells  (per 10/hpf) 
 Mean  Median  Range 
HV-CD 1.5 1 3 
PC-CD 3.6 4 5 
Mixed-CD 4.5 4.5 4 
Pb-CD 7.9 6 16 
 
Multiple comparisons test Summary  Adjusted P 
value 
   
Hyaline vascular type vs. Mixed type *** 0.0007 
Hyaline vascular type vs. Plasma cell  * 0.0423 
Hyaline vascular type vs. Plasmablastic  **** <0.0001 
Mixed type vs. Plasma cell type ns 0.6591 
Mixed type vs. Plasmablastic * 0.028 
Plasma cell type vs. Plasmablastic *** 0.001 
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3.16 LANA-1 and CD20 
Double immunohistochemistry using B-cell marker (CD20) and LANA-1 was performed 
on twenty cases in our cohort. Occasional co-expressing cells were seen, predominantly 




Figure 24: Co-staining LANA-1 and CD20 in Pb CD Double staining 
immunohistochemistry of Pb-CD subtype showing co-staining LANA-1 (nuclear brown) 
and CD20 (cytoplasmic red) cells located predominantly within the follicles (20x obj 
magnification, insert 40x obj magnification under oil).  
 
3.17 LANA-1 and CD3 
Double immunohistochemistry using T-cell marker (CD3) and LANA-1 was performed on 
twenty cases in our cohort. There were no observable cells that demonstrated double 
staining immunoreactivity.  
 
3.18 LANA-1 negative CD 
Interestingly, the 5 cases that were both p24 and LANA-1 negative after 
immunohistochemical analysis were all morphologically classified as HV-CD by the 
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investigators (Figure 25). There were also 5 cases that were LANA-1 negative but showed 
p24 immunoreactivity.  
 
After LANA-1 and p24 immunohistochemical analysis, a total of 10 patients were found 
to be HHV-8 negative. There were 5 HIV negative patients and 5 HIV positive patients.  
The HIV-negative/HHV-8-negative patients showed a female predominance (M:F 2:3) 
and a sex ratio of 0.7:1. There were 3 white (female) patients,  1 coloured male and 1 
African male. Interestingly all 5 cases were classified as HV-CD based on lymph node 
histomorphology. 
 
The HIV-positive/HHV-8 negative patients showed a male predominance (M:F 3:2) and 
sex ratio of 1.5:1. There were 4 African patients (M:F 2:2) and 1 coloured male patient. 
There were 4 cases that were classified as HV-CD and the remaining case as PC-CD. 
Overall, 90% (n=9) of the HHV-8 negative patients were classified as HV-CD.  
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CHAPTER 4:   
DISCUSSION 
 
The current study represents the largest series of Castleman disease investigated in a South 
African setting and it is, to my knowledge, the first immunophenotypic study to use 
double-staining immunohistochemistry to elucidate the pathophysiology and biology of 
HHV-8 infected cells in a Western Cape CD cohort. The previous largest series was 
published by Patel et al. in 2015 and included 35 cases seen over a period of 25 years. 
 
The study cohort included 26 male and 24 female patients (M: F = 1.08:1), mean age 37.7 
years.  There were 16 HV-CD, 16 Pb-CD, 9 PC-CD and 9 mixed-CD subtypes. There was 
an increase in number of patients diagnosed with HIV associated CD over the study 
period, and an increase in the number of cases classified as Pb-CD subtype. There was a 
statistically significant association between HIV and HHV-8 positivity (p < 0.0002).  CD4 
counts and HAART enrolment were not predictive of CD development (p = 0.6120). 
Concurrent Kaposi sarcoma was seen in 16% (n=8) of the cohort. When comparing Pb-CD 
and HV-CD, there were statistically significant differences in density of LANA-1 infected 
cells (p<0.0002), LANA-1/DC-SIGN co-expressing cells (p <0.0072) and LANA-1/p24 
co-expressing cells (p<0.0001). LANA-1/DC-SIGN co-expressing cells were seen in the 
subcapsular sinuses, intranodal sinuses and medullary cords while LANA-1/DC-SIGNR 
co-expressing cells were seen within intranodal sinuses.  The majority LANA-1/p24 co-
expressing cells were localised within the parafollicular and mantle zones of the lymph 
nodes. LANA-1/CD20 co-expressing cells were seen within the follicles and parafollicular 
zones.  
 
The clinical and pathological manifestations of the CD subtypes have previously been 
described in several other small case series (Keller et al., 1972; Frizzera, 1988; Herrada et 
al., 1998; Mylona et al., 2008; Bower et al., 2011). Since 2011, there have been 
publications of larger case series reporting the epidemiology and natural history of CD 
(Dispenzieri et al., 2012; Casper et al., 2013). There have also been a few studies that 
focused on variation of patient subsets within defined CD histological subgroups, HIV 
status and ethnicity (Mylona et al, 2008; Stebbing et al, 2008). 
 
 
                                                                                                                                                 71 
4.1 Incidence and prevalence 
Despite the increasing awareness of the disease among both physicians and pathologists, 
the exact incidence and prevalence of CD, especially HIV-associatedHIV-associated 
MCD, is not yet known in South Africa or sub-Saharan Africa. Consequently, we are not 
able to establish the actual burden of disease. This can be partially attributed to the lack of 
clinicopathological studies coming out of South Africa. The fact that there are also no 
diagnostic/ICD-10 codes that currently exist for CD, UCD or MCD, highlights the rarity 
of CD while at the same time emphasises the need for more recognition of this disease.  In 
countries like the USA where there has a been a surge in interest regarding CD, large 
patient studies have estimated that the annual incidence is in the region of 6500 cases 
(Munshi et al., 2015).  
 
Not only does our cohort show a substantial increase in the frequency of CD diagnosed at 
Groote Schuur hospital during the study period, it also highlights the rising incidence of 
plasmablastic CD since 2006.  These fingings are to be expected given the high 
prevalence of both HIV and HHV-8 infection in our population. Although Pb-CD is 
known to occur with increased frequency in the context of HIV and AIDS, with a few 
international publications addressing its incidence in countries such as the USA and UK 
(Gerard et al., 2007; Powles et al., 2009), there is a distinct absence of regional South 
African statistics. The lack of specific data in South Africa may be related to the fact that 
CD is still a relatively rare disease and therefore not as yet recorded on the National 
Cancer Registry (NCR). HHV-8 seroprevalence is reported to be high in sub-Saharan 
Africa compared to other regions prevalence rates.  
 
In South Africa, a study conducted at an HIV clinic in Johannesburg found a high HHV-8 
prevalence of 48% (Maskew et al., 2011) which correlated with another South African 
study that indicated the HHV-8 seroprevalence varied from 35% to 49% across different 
municipalities in one province (Malope-Kgokong et al., 2010).  A study conducted in the 
Western Cape province of South Africa found the HHV-8 seroprevalence to be 45.45% in 
HIV infected patients without KS (Blumenthal, 2017).  
 
Although, HIV prevalence remains high (12.7%) nationally among the general 
population, there is also interprovincial variation with high prevalence and incidence rates 
in Gauteng and Kwazulu Natal compared low HIV prevalence in Northern Cape and 
 
                                                                                                                                                 72 
Western Cape (South African National AIDS Council, 2012).  Larger studies will   
therefore be of great value in obtaining prevalence and incidence rates of CD, both 
provincially and nationally, as there have been no comprehensive studies to date. 
 
4.2 Patient demographics 
The mean patient age for the entire cohort was 37 years (median age = 36 years and range 
= 14 – 76 years).  The age range for HV-CD was 14 – 76 years, the majority of cases 
occurring between 20-45 years with a mean age of 37.8 years and median of 36 years.  
This is similar to the findings described by Mylona et al. (2008), who reported that 
unicentric HV-CD most commonly presents in the third and fourth decade of life, with the 
mean age of diagnosis being 34 years.  The age range for the PC-CD (including the 
plasmablastic subtype) was 23 – 61 years, with a median of 37 years and mean age of 
38.6 years.  HIV-associated MCD was found to affect mainly men with median age of 40 
years. Other studies observed that HIV-positive patients had a younger age of 
presentation in comparison to HIV-negative patients (Dispenzieri, 2011; Mylona et al., 
2008; Bower et al., 2011).  The median age of onset of HIV-negative individuals was 56 
years (Fagenbaum et al., 2014).  This correlated with our findings which showed a 
median age of 37.7 years for HIV positive patients and 52 years for HIV negative 
patients.  
 
The male to female ratio in this study was 1.08:1. There is, however, variation in the 
literature regarding overall sex distribution. Although Soumerai et al. (2014) observed a 
slight male predominance, which aligned with our cohort analysis, this finding differed 
when compared to a study by Bower et al. (2011) and a systemic review by Mylona et al. 
(2008), where a significant male predominance was reported (87% and 90% respectively). 
 
According to Casper (2005), there is no observable predilection for either sex with regards 
to the HV-CD.  This differed to our cohort study which showed a predominance of 
females (62.5%) within the HV-CD group (M:F = 0.6:1).  This finding correlates more 
closely with a study by Talat et al. (2012) which showed that HV-CD had a slight female 
predominance (1.4:1). HIV-associated PC-CD, meanwhile, is found to mainly affect men 
(Mylona et al., 2008) which differed from our cohort (M:F = 1.3:1), which only showed a 
slight male predominence. This discrepancy might be explained in part by the fact that 
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females, represent a larger proportion of the HIV population in South Africa than in other 
part of the world (Mosam et al., 2008). The sex ratio of the entire cohort is 1.08:1, while 
the sex ratio for HIV/HHV-8-associated CD is 1.10:1.  This finding underscores the shift 
in previously high male HHV-8 seroprevalence rates, to females (Sitas & Newton, 2000; 
Stein, 2008; De Cock et al., 2012).  This variation of sex predominance in the literature 
implies that CD epidemiology is still poorly understood and highlights the fact that more 
studies are required with regards to sex distribution.  
 
Larger studies are required to determine true prevalence and incidence of CD.   Knowing 
the burden of disease and counts of the number of patients affected with CD is required to 
plan appropriately for health care and oncology related services. Prevalence estimates, are 
also useful clinically by providing context for diagnostic decision-making in clinics and 
may be helpful in comparing disease burden across different provinces in South Africa, 
sub-Saharan Africa and the rest of the world.  Accurate incident rates are very important 
as it would assist in disease aetiology, by comparing how the rates vary among different 
subgroups in South Africa or with different exposures to HHV-8.  
 
With uncommon diseases, such as CD, there are understandable challenges because cases 
are fewer and harder to find. These factors definitely necessitate surveys of even larger 
populations to achieve stable estimates (as well as longer durations of observation for 
estimates of incidence), which in turn increase the cost, time, and effort involved in 
executing such studies. Because of these issues, studies using primary data collection to 
determine the prevalence and incidence of diseases such as CD are not common. 
 
4.3 Anatomical location 
Although the first case series reporting occurrences of CD specified the mediastinum as 
the most frequently involved site for lymph node enlargement, subsequent series have 
found cervical, abdominal and axillary lymphadenopathy to be equally common 
(Castleman et al., 1956; Keller et al., 1972; Herrada et al., 1998).  One study has 
documented predominantly mediastinal (60–75%), cervical (20%) and abdominal (10%) 
masses (Bower, 2010) while a subsequent study by Bower et al. (2011) showed axillary 
(88%), abdominal (78%), pelvic (70%), mediastinal (58%) and cervical (35%) 
lymphadenopathy.  In our cohort, there were 27 (54%) unicentric and 23 (46%) 
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multicentric presentations with a preponderance of cervical (52%) and axillary (37%) 
lymphadenopathy observed in UCD.  There was insufficient clinical data to accurately 
link anatomical location with histological CD types.  
 
4.4 Unicentric and Multicentric CD 
Although multicentric CD was initially separated from unicentric CD by its multifocal 
nature, it is now clear that it represents a different disease with different pathogenesis and 
much worse clinical outcome. Virtually all MCD cases in HIV-positive patients are 
associated with HHV-8, although HHV-8 positive MCD has also been known to occur, 
albeit rarely, in HIV-negative patients.  
 
The hyaline vascular subtype was found in 90% of UCD patients but rarely in those with 
MCD, while the plasma subtype was found in only 10% of UCD patients but in 80–90% 
of those with MCD (Waterston & Bower, 2004; Casper, 2005; Dispenzieri, 2012; El-Osta 
& Kurzrock, 2011). Unicentric PC-CD, which accounts for <20% of all CD subtypes, is 
usually characterized by an aggregate of multiple, discretely enlarged nodes within a 
single lymph node chain and is characterised by sheets of polytypic plasma cells within 
the interfollicular zones. The follicles are usually of normal to large size with hyperplastic 
germinal centres and showed no prominent vascularization or hyalinization (Cronin and 
Warne; 2009).  After reclassification, 18% (n=9) of the cases were PC-CD. Furthermore, 
PC-CD cases that showed increased numbers of LANA-1 positive plasmablasts were 
additionally subtyped as Pb-CD.  These plasmablasts were localised in the mantle and 
marginal zones and were characterised by amphophilic cytoplasm and large nuclei with 
one or two prominent nucleoli similar to findings by other researchers (Dupin et al., 2000; 
Brousset et al., 2001; Chadburn et al., 2008).  Eventually, 32% (n=16) of our cases were 
classified as Pb-CD. This finding in our study highlights the rising incidence of 
HIV/HHV-8 associated CD in our patient population. 
 
Plasmablastic CD is currently considered a distinct subtype defined by the unique 
population of HHV-8 infected plasmablasts within the lymph nodes of HIV-infected 
patients. (Dupin et al. 2000). Previous immunohistochemical studies have already 
characterised these HHV-8 infected plasmablasts with the accepted consensus that these 
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cells are in fact B-cell derived and are characterized by CD20+/-, CD19+, CD27+, 
CD38+/-, IgM+ and vIL6+ expression (Du et al., 2001).   
 
Although these cells have characteristic cytomorphological features, virally infected cells 
are difficult to identify on morphology alone.  As LANA-1 is the only protein whose 
expression is stably and consistently detected by immunohistochemistry in HHV-8 
infected cells, the presence of strong dot-like nuclear positivity in these plasmablasts, 
even at low magnification, allowed for quick identification of these cells in our cohort 
(Dupin et al.,1999; Dupin et al., 2000). Although there is no consensus on the specific 
number or percentage of virally infected plasmablasts that is required for diagnosis, some 
researchers have stated that the number of plasmablasts ranged from 1% to 15% of the 
total population of cells in affected lymph nodes and spleens (Du et al., 2001). These 
researchers went on to further demonstrate that cases of plasmablastic lymphoma were 
composed of confluent sheets of plasmablasts with identical immunophenotypic features 
to those of HHV-8 positive mantle zone plasmablasts and microlymphomas. 
 
Although some of our plasmablastic cases showed occasional aggregates and clusters of 
plasmablasts within the mantle zones, none of our cases showed features of 
“microlymphoma” or features suggestive of frank lymphomatous progression. This 
finding is significant as plasmablastic CD, microlymphoma and HHV-8+ plasmablastic 
lymphoma are postulated to represent three stages of a single disease in a background of 
HIV-induced immunodeficiency (Cronin and Warnke., 2009). The recent 2015 Workshop 
of The Society for Hematopathology/European Association for Haematopathology 
recently held a workshop that aimed to review immunodeficiency-related 
lymphoproliferations with plasmablastic and plasma cell differentiation (Chadburn et al., 
2017). One of the conclusions of this workshop was that HHV-8 presence or absence is a 
defining feature in disorders associated with CD and that recognising disease progression 
can be difficult.  
 
4.5 HHV-8 positive CD 
There is geographic variation in the prevalence of HHV-8 seropositivity with more than 
50% seropositivity in sub-Saharan Africa, 20-30% seropositivity in Mediterranean 
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countries and less than 10% in Europe, Asia and USA (Uldrick & Whitby, 2011). There 
were 32 black patients, 6 coloured and 2 white patients.  
 
In regions with high HHV-8 seroprevalence in the general population, there is an equally 
high burden of disease. Two studies based in South Africa revealed an HHV-8 
seroprevalence of 32% and 34.5% (Wilkinson et al., 2002; Sitas et al., 1999). The 
prevalence of HHV-8 antibodies increased with increasing age, increased number of 
sexual partners and decreased with increasing levels of education. In addition, HHV-8 
serum antibodies were more prevalent in Black patients compared to White patients (Sitas 
et al., 1999).  
 
Cross sectional studies aiming to define the seroprevalence of HHV-8 in South African 
populations were undertaken by Malope et al. (2012). They found that HHV-8 
seroprevalence was significantly higher in HIV-infected subjects (P = 0.0005), and that 
HIV-infected subjects had significantly higher lytic and latent HHV-8 antibody levels than 
HIV-negative subjects.   
 
It has already been well established that HHV-8 plays a major pathogenic role in the 
development of HIV-associated MCD.  HIV, in addition to its own pathogenic 
mechanisms, has direct effects on HHV-8 by promoting re-activation and replication of 
latent HHV-8 (Merat et al., 2002).  Currently, it is known that HHV-8 is present in 100% 
of MCD in patients infected with HIV and in only 40% to 50% of HIV-negative cases 
(Soulier et al., 1995; Du et al., 2001).  This was reflected in our study with 40 (90%) of 
our cases showing LANA-1 positivity while 10 cases were LANA-1 negative (5 HIV 
positive and 5 HIV negative).  None of our patients were LANA-1 positive/HIV-negative. 
LANA-1 immunoreactivity was demonstrated on 3 cases previously reported as being 
LANA-1 negative. This discrepancy could be attributed to the fact that the original 
diagnostic stains were done on an automated platform, while manual staining was 
performed on the research slides for this study.   
 
One of the interesting findings not previously described in the current literature is the 
statistically significant difference in density of HHV-8 infected cells between Pb-CD and 
each of the other CD types (p = 0.0002). This supports studies by Schulz (2006), who 
demonstrated that up to 50% of affected cells within the mantle zones of plasmablastic CD 
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lymph nodes can show positive LANA-1 staining (Schulz, 2006). This finding may also 
imply that that Pb-CD patients have higher HHV-8 viral copy numbers, higher HIV viral 
loads and lower CD4 T-cell counts.  
 
Interestingly there was a statistically significant difference in density observed between 
the HV-CD and mixed-CD (p = 0.0291) but no statistically significant differences 
observed between HV-CD and PC-CD (p = 0.0584) or mixed-CD and PC-CD.   
 
 HIV status 
The pathogenic role of HHV-8 is enhanced by HIV-induced immunosuppression. The 
rising incidence of MCD could be attributed to the increased awareness of this disease 
amongst health care professionals or due to the increased number of biopsies and lymph 
node excisions undertaken in clinical scenarios of lymphadenopathy with inflammatory 
symptoms where the disease is suspected. 
 
Maskew et al (2011) confirmed an HHV-8 seroprevalence of 48% in their study of 440 
HIV positive patients based in a Johannesburg clinic. The multivariate analysis of patients 
with HIV-associated MCD by Powles et al (2009), showed that the incidence is 
increasing in the HAART era. Further to this, it was also found that patients with well-
preserved immune function, increased age and short retroviral-status duration predisposed 
to the development of MCD which was in contrast to the factors that predisposed to KS 
(Powles et al., 2009). This data therefore suggests that although both MCD and KS are 
associated with HHV-8, an immunosuppressive state predisposed to KS but not 
necessarily MCD. These investigators hypothesised that the biology of HHV-8 was 
altered in MCD thereby causing a dysregulated immune response resulting in the 
inflammatory cytokine cascade often seen in MCD, which would imply that there was 
relatively well-preserved or increasing immune function in the HAART era.  
 
Previous investigations have shown that more lytic viral proteins rather than latent 
proteins are expressed in MCD compared to KS (Marcelin et al., 2007). Powles et al 
(2009) therefore speculated that the role of HHV-8 in the pathogenesis of MCD is most 
likely influenced by a well preserved immune system as opposed to the course of disease 
observed in KS patients.  
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Our cohort showed that 45 (90%) cases were HIV positive, when re-evaluated for p24 
immunohistochemistry. We were unable to ascertain if the HIV tests done previously 
were HIV-1/2 Ab/Ag ELISA or rapid onsite finger prick tests used at primary health care 
facilities.  After p24 immunohistochemistry analysis, 3 of the 5 patients that were 
originally reported as being HIV negative (ELISA), showed nodal p24 immunoreactivity.  
This discrepancy between ELISA and p24 IHC may be due to the fact that p24 
concentration are often too low between initial infection and detection (window period) 
by the conventional ELISA (Laperche et al., 2012). A literature search looking for reports 
of false positive p24 immunoreactivity within lymph nodes did not reveal any results. 
 
Moonim et al (2010) immunohistochemically evaluated HIV-1 p24 in 123 cases over a 3-
year period, where 37 (30%) cases showed positive expression of p24 in follicular 
dendritic cells (FDCs) with 11 of these 37 cases neither clinically suspected to be HIV 
positive nor having any prior serological evidence of HIV infection (Moonim et al., 
2010). 
 
The presence of HHV-8 in all of our patients with HIV associated CD may be due to an 
HIV-induced cytokine rich microenvironment that is particularly favourable to HHV-8 
replication.  Dupin et al (2000) attributed such a finding to unhindered proliferation of 
HHV-8 in HIV-positive patients, which would ordinarily be more suppressed in 
immunologically competent individuals.  Due to the strong association of HHV-8 MCD 
with HIV infection in our South African sample, we therefore propose that the diagnosis 
of Pb-CD be highly suggestive of immunosuppression in an individual with an otherwise 
unknown immune status. 
 
All 25 patients reclassified with PC-CD (n=9) and Pb-CD (n=16) were HIV positive, 
which correlated with studies that reported that HIV-associated CD is almost always either 
PC-CD or mixed CD (Oksenhendler et al., 1996; Herrada et al., 1998; Mylona et al., 
2008; Powles et al., 2009; Bower et al., 2011; Soumerai et al., 2014). More importantly, 
our study observed an increase in the plasmablastic subtype which is most likely driven by 
the presence and increase in latent gene proliferation of HHV-8 within plasmablastic cells, 
as postulated by Dupin and colleagues (2000).   
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Of the 16 patients with HV-CD, 11 (69%) were HIV infected, which differs from other 
case series that found that HV-CD usually shows no association with HIV infection 
(Mylona et al., 2008; Soumerai et al., 2014). It is possible that our study findings are 
more reflective of the high HIV seroprevalence in our population.  
 
HAART did not prevent the development of CD as 22 of our 45 HIV infected patients 
were enrolled on HAART at the time of diagnosis.  Although there is an increased 
incidence of MCD in HIV-positive patients who have low CD4 counts, the documented 
CD4 counts in our patient cohort ranged from 37 to 879 x 106/l (mean = 270 x 106/l, 
median = 193 x 106/l).  There was no correlation between the occurrence of CD and CD4 
counts in our cohort (p=0.1631). These findings are similar to epidemiological studies 
which found that neither low CD4 counts nor use of HAART was associated with 
development of CD (Mylona et al., 2008; Bower et al., 2011).  It is therefore possible that 
the occurrence of CD after initiation of HAART could be part of an immune 
reconstitution syndrome. 
 
Some studies have even found that the incidence of HIV-associated MCD appears to be 
increasing even in the HAART era (Stebbing et al., 2008).  This is in contrast to the 
decline in the incidence of HIV-associated KS (Mylona et al., 2008).  The exact 
mechanism for this increase is unclear, but may possibly be due to improved survival 
rates, chronic immune dysregulation caused by HIV infection or even chronic immune 
activation by HAART.  
 
 Co-existent Kaposi Sarcoma  
Based on consistent detection of the HHV-8 genome in both KS and MCD in conjunction 
with frequent co-presentations in the same specimen, it is now widely accepted that HHV-
8 plays a critical role in the pathogenesis of both these diseases and that there is in fact, an 
increased incidence of KS in individuals with HHV-8 associated CD (Powles et al., 
2009). PCR analysis shows that HHV-8 is present in all epidemiologic types of KS i.e. 
AIDS-associated KS, classic KS, endemic KS, and posttransplant KS (Moore & Chang, 
1998). The HIV prevalence in South Africa in 2016 was reported as 12,7% with 18.9% of 
population between the ages of 15-49 years being affected (STATSSA).  HHV-8 
seroprevalence in the HIV population is between 44% and 48% (Malope et al., 2008; 
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Maskew et al., 2011) with an almost 50-fold increase in risk for developing KS (Stein, 
2008). 
 
HAART is effective on KS as seen by the regression of KS in individual cases and a 
dramatic fall in overall incidence which can be attributed to improving immune function 
with HAART use (Powles et al., 2009).  Data also suggests that KS is dependent on the 
host’s immune status and CD4 counts (Bower et al., 2009). KS should be diagnosed with 
both histology and immunohistochemistry. Anti-LANA-1 immunohistochemical staining 
with characteristic nuclear speckled staining of spindle cells, shows that the viral protein 
is expressed in KS cells, regardless of clinical type or disease stage (Dupin et al., 1999). 
PCR analysis can even be performed on formalin-fixed paraffin-embedded KS tissue to 
confirm diagnosis based on the identification of HHV-8 DNA fragments in the tissue and 
occasionally in the sera of KS patients (Asahi-Ozaki et al., 2006).    
 
Eight cases (16%) of concurrent KS and CD were identified in our cohort of 50 CD cases. 
The microscopic diagnosis of KS in our study was confirmed by nuclear positivity for the 
LANA-1 in KS cells within the lymph node capsule, subcapsular sinuses and hilum.  The 
presence of these focal subcapsular spindle cell proliferations has been attributed to the 
virus remaining localised within the subcapsular sinuses, as suggested by O’Leary et al 
(2010). Although the origin of KS cells is thought to be endothelial cells, the protein 
expression of KS cells is very different from that observed in vascular endothelial cells as 
HHV-8 induces an increase in lymphatic endothelial markers (Hong et al., 2004).  This 
was also observed in study by Dupin et al (1999) who showed the similar distribution of 
VEGFR-3, a lymphatic marker, and HHV-8 in both early and late KS lesions. 
 
All of our cases with KS showed features of early KS consisting of microscopic foci of 
KS spindle cells within the capsule and hilum as opposed to advanced KS which often 
effaces most of the lymph node architecture. This emphasises that these foci can easily be 
missed in routine histological evaluation or even after immunohistochemistry. 
 
As LANA-1 is expressed in the nucleus of KS cells and is responsible for establishing and 
maintaining latency, it can therefore be reasoned that latent infection is important for the 
pathogenesis of KS infection. Our cohort was too small to correlate with published 
findings which showed that patients with HIV-associated CD have a 54% to 72% risk of 
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being diagnosed with KS, either concurrently or sequentially and that the two diseases 
may coexist in the same pathological specimen (Mylona et al., 2008; Naresh et al., 2008). 
Although lytic gene expression is limited in KS, HHV-8 encoded lytic proteins such as 
vIL-6 which interacts with the human IL-6 receptor and partially mimics its function, are 
important for KS pathogenesis and can be detected at high levels in KS patient’s sera (Liu 
et al., 1997). vIL-6 can also be detected at high levels in the sera of MCD patients 
(Parravicini et al., 1997). It is the elaboration of vIL-6 in KS, which also causes a 
proliferation of plasma cells and increased angiogenesis, can eventually contribute to the 
concurrent development of CD in a setting of HHV-8 infection.  This interaction may also 
explain the formation of LANA-1 positive KS ‘tumourlets’ within a background of CD 
(O’Leary et al., 2010).  
 
Other studies that have also investigated the association of these two entities postulated 
that it was most likely due to both latent and lytic infection of B-cells by HHV-8 in MCD, 
which in turn leads to a wide variety of susceptible cells within the lymph node being 
exposed to very high levels of the virus (Abe et al., 2006; Naresh et al., 2008).   
 
Apart from the latent and lytic genes that are expressed by HHV-8, studies have also 
identified miRNAs that have been shown to affect KS tumour biology by modulating host 
gene expression profiles (Samols et al., 2007). None of our HIV-negative patients showed 
evidence of concurrent KS which correlated with studies that showed that the association 
of KS is lower with HIV-negative MCD patients, where the reported dual incidence is 
between 0% and 13% (Mylona et al., 2008). This is in contrast to iMCD which shows no 
association with either virus.  
 
 Dual staining LANA-1 and DC SIGN/DC-SIGNR 
HHV-8 infection of target cells involves both multiple host cell surface receptors and viral 
envelope glycoproteins.  DC-SIGN has emerged as a key player with regards to HHV-8 
infection of monocytes, MDDCs, monocyte-derived macrophages, B-cells, Langerhans 
cells, interstitial cells, and plasmacytoid dendritic cells (Rappocciolo et al., 2006; 
Rappocciolo et al., 2008; Knowlton et al. 2014).  The identification of co-expressing 
LANA-1 and DC-SIGN/DC-SIGNR in our study correlates with Hensler et al. (2014) who 
have already previously demonstrated that HHV-8 glycoprotein B serves as a viral 
attachment protein responsible for binding to cellular receptor DC-SIGN.   
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In our study, DC-SIGN expressing cells were located in paracortical sinuses, within 
medullary cords and along the capsule and trabeculae of lymph nodes. Cells expressing a 
low level of DC-SIGN and DC-SIGNR were also scattered in the sinuses, the medullary 
cords and in the perifollicular zone of the paracortex. The above findings can be accounted 
for by the fact that although DC-SIGN expressing cells are present in all lymphoid organs, 
in lymph nodes the majority of these dendritic cells are located near the entry points for 
lymph, specifically in the cortical sinuses, whereas most DCs in the paracortex fail to 
express DC-SIGN. (Soilleux, 2003).  This, coupled with the expression of DC-SIGNR by 
very restricted subsets of endothelial cells, may explain the localisation for co-expressing 
cells seen in our study.  
 
Although the exact mechanism of how HHV-8 travels to and infects cells within lymph 
nodes is not completely understood, Campbell et al (2014) have postulated that after 
infection of the mucosal epithelium by HHV-8, the virus most likely infects blood and 
tissue DC-SIGN expressing monocytes and macrophages to gain access into the draining 
lymphoid organs where it then interacts with resident B and T cells. We were able to 
clearly demonstrate this distribution of HHV-8 infected DC-SIGN/DC-SIGNR expressing 
cells from the periphery of the lymph node (sinuses) into the follicles. 
  
Several investigations have also found HHV-8-infected B-cells in the mantle zones of 
lymph nodes from patients with KS, MCD and nodal PEL (Dupin et al., 1999). This 
would therefore imply that DC-SIGN is also expressed within the parafollicular zones of 
lymph node tissue. Although our particular study has not demonstrated co-expression of 
HHV-8 and DC-SIGN in B-cells, other investigators have already done so (Rappociolo et 
al., 2006). These cells may serve as a source of latently infected B-cells that can 
potentially undergo oncogenic transformation and subsequently increasing the risk of 
HHV-8-related lymphoma development.  
 
LANA-1 is not detectable in follicular dendritic cells (FDC) within lymph nodes isolated 
from KS, PEL, and MCD patients (Dupin et al., 1999). Other authors, in contrast, found 
that a proportion of FDCs expressed LANA-1 which was associated with an enhanced T-
cell response and increased T-cell infiltration into lymphoid organs (El-Daly et al., 2010).   
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In our study, co-staining LANA-1/DC-SIGN and LANA-1/DC-SIGNR cells were only 
occasionally seen. The low numbers of these co-expressing cells may be attributed to the 
findings that HHV-8 infection of MDDCs, SMDCs and blood circulating monocytes is 
associated with a decrease in DC-SIGN expression (Rappocciolo et al., 2006). 
Interestingly, it has been suggested that K3 and K5, both HHV-8 encoded proteins, have 
the ability to decrease levels of DC-SIGN and DC-SIGNR on the surface of virus-infected 
kidney cells (Lang et al., 2013), but it has yet to be revealed if LANA-1 functions in this 
manner in DCs within affected lymph nodes. Available data also suggests that DC-SIGN 
is positively regulated in response to extracellular pathogen-based immune responses and 
is negatively regulated in response to intracellular pathogen-based responses such as viral 
infections (Relloso et al., 2002; Rappocciolo et al., 2006). This theoretically could explain 
the fewer than expected numbers of HHV-8 infected dendritic cells in our study.  
 
Despite the small number of co-staining cells observed in our study, there was a 
statistically significant difference in the number of LANA-1/DC-SIGN and LANA-1/DC-
SIGNR co-expressing cells observed between HV-CD and Pb-CD (p = 0.0072). There was 
also a statistically significant finding between HV-CD and PC-CD (p = 0.0458). There 
were no other statistically significant findings between the other CD types.  
 
The presence of co-staining cells seen in the vicinity of sinuses and surrounding medullary 
cords can be attributed to lymphatic homing receptors, such as CCR which are up-
regulated, to attract them to CCL19 and CCL21 expressing high endothelial venules 
(HEVs), which triggers the migration of DCs into lymphatic vessels and to draining lymph 
nodes (Holmgren and Czerkinsky, 2005). We were also able to observe the distribution of 
co-localising cells within the subcapsular and intranodal sinuses, perivenular zones, 
follicles and germinal centres where they subsequently came into contact with naïve B-
cells.  
 
HHV-8 is one of the few human viruses that primarily targets APCs, 
monocytes/macrophages and polyfunctional B lymphocytes for infection, altering their 
cytokine profiles, manipulating their surface expression of MHC molecules and altering 
their ability to activate HHV-8-specific T-cells (Knowlton et al., 2014).  Our findings are 
of importance as it further solidifies evidence that DC-SIGN serves as an entry receptor 
for HHV-8. This is also supported by the fact that most of the major cell types that can be 
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infected with HHV-8, express DC-SIGN and that infection of these cells can potentially 
be blocked by anti-DC-SIGN antibodies or natural ligands for DC-SIGN. This was also 
demonstrated in a study Rappocciolo et al. (2008) where active infection of blood and 
tonsillar B-cells expressing DC-SIGN by HHV-8 could be blocked with the use of anti-
DC-SIGN monoclonal antibody. Hence DC-SIGN and the closely related C-type lectin 
DC-SIGNR, may provide the key to the development anti-viral therapies designed to 
prevent HHV-8 infection and spread. 
 
 Dual staining LANA-1 and p24 
We already know that HHV-8 seroprevalence is higher in HIV-infected compared to 
HIV-uninfected population.  Viral co-infection, with associated increased cellular 
proliferation and transformation, often represents a common mechanism in the 
pathogenesis of malignancies especially affecting immune compromised hosts. 
 
The simultaneous detection of co-infecting viruses within the same neoplastic cells is seen 
in other HIV related malignancies such as HIV-associated PEL cells harbouring EBV and 
HHV-8 viruses (da Silva & de Oliveira, 2011), and implies viral co-operation in 
oncogenesis and subsequently lymphomagenesis.  HIV represents one of the main viruses 
that cooperates with other viruses in the induction of cancers.  
 
In our study, LANA-1/DC-SIGN co-expressing cells were also seen within the lymph 
node sinuses which is supported by the findings of Casselli et al. (2005) that the presence 
of HHV-8 activates HIV replication during macrophage passage through the endothelial 
barrier.  As a result of this circulating monocytes produce significantly higher amounts of 
HIV in the presence of HHV-8.  This was also illustrated by our cohort with a statistically 
significant association between HIV and HHV-8 infection (p-value = 0.000002). Although 
there has been intensive research done on HIV and HHV-8 cellular targets, the 
identification of co-staining LANA-1/p24 cells in CD in our study is a result not 
previously described. Previous studies have shown that DC-SIGN binds host ICAM-2/3 as 
well as HIV gp120 ligands on separate sites of the DC and is able to transmit the virus to 
activated B-lymphocytes (Geijtenbeek et al., 2002; Su et al., 2003). Closely related DC-
SIGNR, although expressed by restricted subsets of endothelial cells, has similar ICAM-3 
and HIV-binding properties to DC-SIGN (Soilleux, 2003).  
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We know that p24 immunoreactivity localises to follicular dendritic cells due to the 
presence of transmissible HIV particles on the surface of FDCs which are in very close 
contact with surrounding T- and B-cells.  We can therefore surmise that the co-staining 
LANA-1/p24 cells in our study are follicular dendritic cells. This conclusion is supported 
by El-Daly et al (2010) who demonstrated that LANA-1 was present on follicular 
dendritic cells in a proportion of MCD cases. Furthermore, it was also shown that the 
LANA-1 positive FDC subgroup of patients had significantly higher numbers of T cells 
within the follicles in comparison to the LANA-1 negative FDC subgroup (p = 0.047). 
 
It has also been demonstrated that HIV is internalised by B-lymphocytes after binding DC-
SIGN (Rappocciolo et al., 2006).  The same investigators then demonstrated that HHV-8 
infects and replicates in activated B-lymphocytes via DC-SIGN (Rappocciolo et al., 2008). 
Using this data, we can also therefore assume that some of the cells that express both 
LANA-1 and p24 in our study are most likely to be co-infected B-lymphocytes.  This 
raises many questions regarding the important role that FDCs play in the transmission 
kinetics of both HIV and HHV-8. FDCs unlike other dendritic cells do not express DC-
SIGN or DC-SIGNR which prevents internalisation of HIV thereby making transmission 
to adjacent T- and B-cells all the more effective (Keele et al., 2008).  Interestingly, El-
Daly (2010) also found that the LANA-1 positive FDC subgroup had fewer numbers of 
LANA-1 infected plasmablasts and lower HHV-8 viral copy numbers than the LANA-1 
negative FDC subgroup (not statistically significant).  
 
Our Pb-CD had statistically significantly higher numbers of LANA-1 infected 
plasmablasts, LANA-1/DC-SIGN, LANA-1/DC-SIGNR and LANA-1/p24 co-staining 
cells when compared to the other CD subtypes.  It would be a valuable endeavour to 
explore this fascinating enigma further as I postulate that FDCs may serve as reservoirs of 
both HIV and HHV-8 and may be a crucial cellular target that unlocks the secrets of 
HIV/HHV-8 associated CD.    
 
It is also probable that some HHV-8 encoded viral products, homologous to cellular 
chemokines, induce inflammatory cytokine production in monocytes, macrophages, 
dendritic cells and endothelial cells which in turn influences HIV replication as MDDCs 
and T-helper cells are the most frequently HIV-infected cells in the bloodstream and 
primarily responsible for HIV dissemination in tissues and organs (Caselli et al., 2005).   
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We know that LANA-1 interacts synergistically with HIV tat protein in the transactivation 
of HIV LTR, which would therefore increase cell susceptibility to HIV in the presence of 
HHV-8.  The alteration of DC function brought about by HHV-8 binding also affects T 
lymphocyte responses, which promotes an opportunitistic environment for HIV to cause 
further deterioration of the immune system.  In addition, in the presence of HHV-8, DCs 
were able to capture more HIV virus and increase transfer to susceptible cells (Liu et al., 
2013).  As there is increased susceptibility to HIV in both natural target cells such as T-
lymphocytes and otherwise non-permissive cells, such as B-lymphocytes, this 
cumulatively increases the the opportunity for B-lymphocytes to serve as reservoirs for 
both viruses.  
 
The role of HIV tat in oncogenesis has been extensively studied.  Studies show that HIV 
tat can also directly activate the lytic replication of HHV-8 by regulating the JAK/STAT 
signalling pathway (Aboul-ela et al, 1995). Other studies have demonstrated that tat also 
acts through additional pathogenetic mechanisms, which include upregulation of IL-6 
expression and other angiogenic factors.  Given the central role of IL-6 in the 
pathogenesis of MCD, HIV effects mediated by tat may also represent a central 
proliferative mechanism in MCD.  Collectively, the above mentioned findings strongly 
suggest that tat plays a pivotal role in HHV-8-associated proliferations. The reverse 
mechanism of cooperation includes the activation of HIV LTR by herpesviruses that 
increases HIV replication, which further decreases immune competency and immune 
surveillance.  HHV-8 takes advantage of this mechanism by also interacting physically 
and synergizing with HIV tat to increase retroviral transcription (Huang et al., 2001).  
Furthermore, tat increases the proliferative capacity and cell cycle progression of 
herpesvirus infected, immortalized B lymphocytes, which promotes B cell 
lymphomagenesis (da Silva & de Oliveira, 2011).  It is therefore plausible that HHV-8 
infected cells, in patients with concurrent HIV infection, likely come into contact with 
cells supporting active HHV-8 infection and replication, or even be co-infected by both 
viruses. Endothelial cells and monocytes may therefore represent other potential sites of 
interaction between these two viruses.  
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 Dual staining LANA-1 and CD20 
Immunohistochemical analysis of our cohort revealed occasional double-expressing 
LANA-1 and CD20 cells, correlated more with the findings of Dupin et al (1999), 
however Paraviccini et al (1997) and Chadburn et al (2008) did not confirm these 
findings. Dupin et al (1999) also demonstrated that HHV-8 infected cells do not stain with 
immunoblast marker (CD79a) or B cell activation markers (CD23, CD38, CD30).  
 
We already know that HHV-8 infection can expand the range of cells that could act as 
potential reservoirs for HIV infection by allowing for non-permissive B-cells to be 
become infected.  Knowlton et al (2014) demonstrated that although HHV-8 targets naïve 
B-cells which include plasmablast-like cell populations, it is still unclear whether these B-
cells are directly infected by the virus or if they are the result of infected precursors.  
Plasmablasts are rarely observed in normal lymph nodes.  
 
Although HHV-8 infected B-cells comprise a very small proportion of the total cell 
population in CD, the plasmablastic subtype can show drastically increased numbers 
within the mantle zones. The plasmablasts in MCD are generally larger than the 
surrounding HHV-8 infected CD20 positive B-lymphocytes, harbour both latent (LANA-
1) and lytic (vIL-6) profiles and do not express B-cell antigens (CD20, CD79a, PAX-5).  
They also express high levels of cytoplasmic IgM λ immunoglobulin, are usually 
MUM1+, CD138-, and CD30 weak+ (Dupin et al., 2000; Oksenhendler et al., 2002). 
Shulte and Talat (2010) went further in their immunohistochemical characterisation of 
these HHV-8 infected plasmablasts by successfully using double staining 
immunohistochemistry to demonstrate compartmentalization between plasmablasts and 
plasma cells. One consistent finding amongst all investigators was the downregulation of 
CD20 and other B-cell marker expression within the plasmablast population.  This is 
important when we consider that rituximab therapy is usually successful. 
  
Dupin et al (1999 and 2000) observed that at least 10-30% of the LANA-1 positive cells 
localized predominantly in the mantle zone of the follicles and that these plasmablasts 
were not present in HHV-8 negative MCD or HV-CD.  
 
B-cell involvement was confirmed by studies that identified HHV-8 driven elaboration of 
both vIL-6 and hIL-6 by B-cells in the mantle zones of lymph nodes (Aoki et al., 1999; 
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Pinto and Nunes, 2011).  In studies conducted by Chadburn et al. (2008) and Naresh et al. 
(2009), it was also observed that the majority of the HHV-8 infected cells within affected 
lymph nodes, were in fact B lymphocytes that supported either latency or lytic replication. 
 
Our use of double immunohistochemical staining with CD20 and LANA-1 allowed us to 
identify virally infected B-cells as described by Naresh et al. (2009).  Similar studies 
conducted on bone marrow biopsies of patients with HHV-8 associated MCD also found 
that a subset of LANA-1 positive cells were CD20 positive (Bacon et al., 2004).  Our 
finding of LANA-1 and CD20 co-expressing cells, primarily extrafollicular in location, 
correlated with studies conducted by Chadburn et al (2008), who characterised the 
infected cells as pre-terminally differentiated B cells. A study using ex vivo HHV-8 
infection of tonsillar cells suggested that HHV-8 preferentially targets λ light chain- 
expressing B-cells for stable latent infection as it was demonstrated that there was a larger 
subset of λ than κ cells that were latently infected with HHV-8 (Hassman et al., 2011). 
 
Our study allowed us to demonstrate that the number of the double expressing LANA-
1/CD20 cells observed in the both the PC-CD and Pb-CD subtypes, although low, were 
still greater than numbers seen in the HV-CD subtype, findings which have not previously 
been reported. Low numbers of co-expressing cells are likely related to the 
downregulation of CD20 expression as a result of HHV-8 infection (Rappocciolo et al., 
2008).  
 
Another possible explanation is most likely due the fact that despite the significantly 
higher HHV-8 DNA levels in MCD, the virus persists mainly in its lytic form within B-
lymphocytes (while remaining latent in KS- and PEL-infected cells) (Stebbing et al., 
2011; Powles et al., 2009).  Although B-cells are an important reservoir of latent HHV-8, 
other studies have also shown that other HHV-8 encoded lytic proteins, such as K8, K8.1 
and vIL6 can also be detected in these infected cells, confirming that MCD is associated 
with lytic as well as latent HHV-8 infection (Dupin et al., 1999; Katano et al., 2000a).   
 
It is therefore logical that some researchers have postulated that HHV-8 infection 
establishes both latent and lytic infection in naïve B-cell subsets, which most likely causes 
an early viral-driven cellular differentiation into plasmablasts in plasmablastic CD and a 
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pre-terminal plasma cell stage of differentiation in PC-CD, while some cells still continue 
to support the lytic cycle (Paraviccini et al.,1997; Dupin et al., 1999).   
 
 Dual staining LANA-1 and CD3 
Our study did not show LANA-1 and CD3 co-expressing cells which correlates with other 
authors who have previously demonstrated that infected cells do not stain with T-cell 
markers. (Parraviccini et al., 1997; Dupin et al., 1999). 
 
Specific MHC class I restricted (CD8+) responses to HHV-8 protein epitopes have been 
reported (Wilkinson et al., 2002). This highlights the important ability of cytotoxic CD8+ 
T lymphocytes (CTLs) to kill virally infected cells in response to intracellular viral 
antigen. These T-cell responses are possibly sufficient to control primary HHV-8 infection 
in immunocompetent individuals. DC-SIGN and DC-SIGNR are not expressed on T-cells 
and HHV-8 is not able to directly enter T cells (Geijtenbeek et al., 2000). In 
immunocomprised individuals however, it is also known that latent HHV-8 directly affects 
this ability of dendritic cells to activate virus specific CD8+ T cells (Rappocciolo et al., 
2006). This most likely alters T cell responses and allows for active lytic and latent 
infection of susceptible cells, such as B-lymphocytes. Interestingly, CD4+ T-cells are 
suggested to support latent HHV-8 infection in B-cells by reducing the viral lytic cycle 
(Myoung & Ganem, 2011). This could possibly explain why even patients with adequate 
CD4 counts are suspectible to HHV-8 associated CD.  
 
It has also previously been demonstrated that T-cell responses to HHV-8 antigens in HIV-
infected individuals were low and that altered DC function by HHV-8 leads to decreased 
activation of T-cells (Guihot et al., 2006 ;  Rappocciolo, et al., 2006).  Based on previous 
epidemiological data, inadequate or altered T-cell function with ineffective control of 
virus replication, are important reasons for increased susceptibility to HHV-8 disease. 
This potentially implicates abnormalities that occur in DCs as a basis for T-cell 
dysfunction during HHV-8 infection. 
 
4.6 HHV-8 negative cases 
All the patients in our study fulfilled the histopathological criteria for CD, with 10 cases 
being immunohistochemically non-reactive for LANA-1 (5 HIV-positive and 5 HIV-
negative).   
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A grading system has also been proposed for the pathological features observed in iMCD 
(0-3) and criteria for histopathological grading include germinal centre atrophy, follicular 
dendritic cell prominence, vascularity, germinal centre hyperplasia and plasmacytosis. It 
is interesting to report that our HHV-8 negative cases showed hypervascular pathology 
(atrophic germinal centres and FDC prominence) rather than plasmacytic features 
(hyperplastic germinal centres and plasmacytosis).  
 
None of our HHV-8 negative cases (HIV-positive and HIV-negative) showed evidence of 
microscopic KS or the presence of plasmablasts.  Although studies have shown that HIV 
infection itself is not necessary for KS development, it is associated with an increased 
incidence and a more aggressive course as HIV infected cells produce several 
inflammatory and growth promoting cytokines that influence the inflammatory milieu. 
The incidence of KS in our HIV seropositive patients compared with our HIV 
seronegative patients may be attributed to higher HHV-8 viral loads in those co-infected 
with HIV. One criterion not included in our study, but which would have added weight to 
the histopathological diagnosis, is detectable HHV-8 viraemia, either measured in the 
plasma or peripheral blood mononuclear cells.   
 
More recently, Liu et al (2016), in a systematic review, provided comprehensive 
information regarding the clinical features, treatments and outcomes of iMCD. 
Fajgenbaum et al. (2017) have presented an evidence based consensus of international 
major and minor diagnostic criteria development for the diagnosis of idiopathic MCD that 
is aimed at assisting in the prompt recognition and effective management of this disease.   
 
4.7 Study limitations 
As this was a restrospective study based solely on records kept in the Division of 
Anatomical Pathology, clinical data was limited. Data regarding viral load, CD4 counts 
and extent of disease were not available in some of our cases and additional information 
regarding whether patients were enrolled on HAART at time of diagnosis could not be 
retrieved. Retrospective studies are also subject to selection bias which can negatively 
impact the accuracy of the results. In addition, the audit was restricted to data obtained 
from a single hospital, specifically GSH.  As GSH is a tertiary hospital, patients treated at 
this hospital are likely to have a greater burden of disease (i.e. lower CD4 counts, more 
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advanced HIV infection and greater seroprevalence of HHV-8) than those treated at local 
clinics. The prevalence and incidence rates of a disease are among the most fundamental 
measures in epidemiology, both of which differ across populations and time. Although our 
cohort number of 50 patients was the largest to date in South Africa, the number is still 
relatively small when compared to other cohorts in USA and the UK. It is imperitive 
therefore that larger studies be conducted in South Africa so that important measures like 
prevalence and incidence estimates can be validated, the importance of which lies in 
establishing accurate disease burdens, susceptible populations at risk and survival 
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CHAPTER 5:  
CONCLUSION AND FUTURE RESEARCH 
5.1 Conclusion 
This study represented the largest cohort of HIV positive, HHV-8 associated Castleman 
disease patients in South Africa as well as the largest double-staining 
immunohistochemical analysis to date. Some of our results confirmed the findings of 
previous studies while other findings have not been described before and is our attempt to 
contribute to the expanding body of work already generated by this intriguing disease. 
 
Our effective utilisation of LANA-1 in double staining immunohistochemical techniques 
not only identified co-staining DC-SIGN, DC-SIGNR and p24 cells, but increased 
numbers (statistically significant) in the plasmablastic subtype in comparison to other the 
CD subtypes which raises many additional questions regarding HIV-associated MCD. 
The plasmablastic CD subtype is morphologically characterised by ‘plasmablasts’ that 
show LANA-1 immunoreactivity. Pb-CD cases in our study showed an increased number 
of LANA-1 staining cells when compared to HV-CD (statistically significant) in addition 
to increased numbers of co-staining cells which may suggest that high HIV viral loads 
and/or low CD4 counts may be responsible for the findings observed.  
 
Further to this, our findings of a statistically significant density of HHV-8 infected 
plasmablasts in Pb-CD, may potentially assist in identifying and/or refining specific 
histopathological criteria that could 1) predict HIV status in CD patient with an unknown 
HIV status, 2) predict outcomes in affected patients and 3) identify patients at risk of 
developing HHV-8 associated NHL (plasmablastic lymphomas or large B-cell 
lymphomas).  
 
Our study also confirmed that DC SIGN and DC-SIGNR are both important requirements 
for HHV-8 entry into cells, that they represent a common ligand pathway utilized by both 
HIV and HHV-8 for viral entry and replication and that dendritic cells expressing DC-
SIGN/DC-SIGNR are key players in HHV-8 infection and pathogenesis. I postulate, 
however, that dendritic cells that do not express DC-SIGN or DC-SIGNR such as 
follicular dendritic cells and Langerhans cells are also instrumental in dual HIV and 
HHV-8 replication and transmission.  
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We also confirmed that HHV-8 primarily infects cells that stain with CD20 and not cells 
that express common T-cell markers, such as CD3, which correlated with studies by 
previous investigators. It is still, however, unclear whether all B-cell lineage subsets are 
equally susceptible to HHV-8 lytic and latent infection, or if B-cell subset precursors are 
infected and as a result of active HHV-8 infection, driven into plasmablastic 
differentiation.  
 
5.2 Future Research 
I therefore feel that it is of fundamental importance to investigate if Pb-CD is directly 
associated with the severity of HIV-associated immunosuppression, which may ultimately 
reflect different pathogenetic mechanisms.  
 
Future studies on larger cohorts of CD should also evaluate the correlation between the 
diagnosis of CD and the clinical state of immunosuppression as measured by the CD4 
counts and HIV viral loads of the patient. Based on results from this study, it would also 
be interesting to see if any correlation exists between the degree of HHV-8 infection of B-
cell subsets, specifically plasmablasts, and the CD4 count.  
 
The prognostic implications of the CD4 counts at the time of diagnosis should at the same 
time also be evaluated through meticulous clinical follow-up of patients diagnosed with 
the disease. Should there be a correlation between the CD4 count and the degree of B-cell 
HHV-8 infection and eventually between the CD4 count and the prognosis of such a 
patient, it could serve as both histological and clinical prognostic markers for these 
patients. It is already known that the presence of HHV-8-positive plasmablasts in HIV-
associated MCD identifies a distinct sub-group of patients with poor survival rates.  
 
Although the potential for anti-DC-SIGN/DC-SIGNR therapeutic agents can be 
envisaged, there is still uncertainty whether these ligands are solely responsible for viral 
binding and entry. It has already been shown in previous studies that HHV-8 is capable of 
expanding the range of targets it infects as well as adapting to different host environments 
by utilising both ‘receptor flexibility’ and ‘molecular mimicry’. Full understanding of 
HHV-8 attachment biokinetics with different cellular targets is therefore imperative to the 
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development of targeted therapies that can prevent both primary infection and spread. Our 
results may also assist in providing further insight into the possible mechanisms that both 
HHV-8 and HIV utilise for immune evasion. The diverse and specialised functions of DC 
and its widespread distribution in the body undoubtedly plays an important contributory 
role in susceptibility of cells for both HIV and HHV-8 infection and therefore provides an 
important converging point for investigating the interaction between these two viruses.  
 
The combined use of LANA-1 (HHV-8) and p24 (HIV) antibodies in our study, allowed 
us to not only identify co-infected cells, but to also observe their distribution within the 
lymph node, not previously described in other studies. Previous studies have shown that 
HHV-8 infects cells by binding to the DC-SIGN in a region that overlaps the HIV gp120 
binding sites. Based on our results of co-infected cells, it may be possible to intentionally 
alter specific regions of DC-SIGN/DC-SIGNR that are key sites for binding of HHV-8 
and HIV glycoproteins, which could potentionally prevent viral infection. The similar 
binding sites in human DC-SIGN/DC-SIGNR for HHV-8 and HIV gp120 therefore 
represent novel targets for therapeutic interventions as well as microbicide and vaccine 
development efforts. The true relationship between HIV/AIDS, HHV-8 infection and CD 
should therefore be further considered in detailed molecular pathology, genetic and 
virology studies.  
 
I also strongly believe that there may be broad genetic and molecular variation in CD 
which definitely warrants further investigation. The elucidation of the molecular pathways 
in this disease will not only assist in further refining its classification, but will also 
improve overall diagnosis.  
 
Although there has been progress in the elucidation of many HHV-8 encoded proteins and 
their in vitro functions, future studies investigating the role of HHV-8 infection and 
transformation of B-cells and endothelial cells in CD can assist in bridging the gap in our 
knowledge between the dendritic cell viral reservoir and lymphomagenesis in HHV-8 
associated CD. There is also limited amount of data assessing T-cells and FDCs in MCD. 
FDCs may in fact play an important role in immune defense mechanisms against HHV-8 
and FDC interactions with T- and B-cells therefore warrant further investigation.  
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Finally, I also propose that a grading system using defined histopathological and 
immunophenotypic criteria for each subtype of HHV-8+/HIV-associated CD, based on 
consensus haematopathological review, be established. This proposed grading system, 
while identifying important major and minor diagnostic criteria crucial for early and 
accurate diagnosis, should also include pertinent laboratory, histopathological and 
immunohistochemical findings.  
 
It is our hope that the results of this study will not only generate further comprehensive 
understanding of the HIV/HHV-8 co-infection microenvironment that is crucial in the 
evolution of this disease, but will also potentially lead to improved therapeutic strategies 
for affected patients.   
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APPENDIX 1: DATA COLLECTION TEMPLATE 
 
Case No. CD1 ….CD50 
Age     
Gender     
Race     
HIV status     
CD4 count     
HAART     
Lymphadenopathy (localised vs generalised)     
Site of Lymph node presentation     
Kaposi Sarcoma     
Disa Report Classification of Castleman variant     
Revised morphological classification     
Disa LANA-1 status     
Revised LANA-1 IHC     
Disa HIV status     
Revised P24 IHC     
LANA-1/DC-SIGN/DC-SIGNR co-localisation     
LANA-1 density /10hpf     
Prescence of co-localised cells     
DC SIGN/ LANA-1 density /10hpf     
DC SIGN/ LANA-1 density /10hpf     
Total of co-stained cells     
Presence of P24/LANA-1     
P24/LANA-1 density /10hpf     
P24/LANA-1 co-localisation     
DC SIGN localization     
DC SIGNR localization     
P24 localization     
LANA-1 localization     
CD20 localization & co-localised cells (CD1-20)     
CD3 localisation & co-localised cells (CD1-20)     
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APPENDIX 2: ETHICS PROTOCOL APPROVAL 
 
